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ABSTRACT 
This thesis comprises of five chapters. The first chapter is the general 
introduction which explains the importance of analytical chemistry, particularly in 
the field of pharmaceutical analysis and its role in testing the medicine before it is 
made available to the public. The drugs may contain impurities resulting from the 
raw materials and reagents, as reaction by-products and through degradation during 
manufacture and storage. The classification of such impurities is discussed. The 
drugs in bulk and dosage forms are generally determined by physical, chemical, 
physico-chemical and biological methods. The various analytical techniques used in 
pharmaceutical analysis are also reviewed. Analytical methods that are used for 
quantitative determination of drugs in pharmaceutical and biomedical samples play 
a significant role in evaluation and interpretation of bioavailability, bioequivalence 
and pharmacokinetic data. Method validation is an important component in 
determining the reliability and reproducibility of an analytical procedure. Therefore, 
overall method validation strategy has been discussed. A brief description of 
antianginal drugs with special reference to calcium channel blockers is included. So 
far nine calcium channel blockers have been approved for clinical use which have 
different chemical structures. On the basis of chemical structures, the classification 
of these drugs is also presented. 
Second chapter describes a new, simple, sensitive, rapid and accurate kinetic 
method for determination of nifedipine in pure form and pharmaceutical 
preparations. The method is based on the oxidation of drug with potassium 
permanganate at pH 7.2+0.2. The reaction is followed spectrophotometrically by 
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measuring the rate of change of absorbance at 530 nm. The calibration graph is 
linear in the concentration range of 18 - 44 |ig ml"'. The method has been 
successfully applied to the determination of nifedipine in pharmaceutical 
preparations. The results obtained by both the proposed method and British 
Pharmacopoeia method were in good agreement and statistical comparison by 
student's t-test showed no significant difference between two methods. 
In third chapter, spectrophotometric methods for determination of diltiazem 
hydrochloride have been discussed. This chapter is divided into two sections, 
namely: 
[A] Extractive spectrophotometric methods for determination of diltiazem 
hydrochloride in pharmaceutical formulations using bromothymol blue, 
bromophenol blue and bromocresol green. 
[B] Spectrophotometric determination of diltiazem hydrochloride with sodium 
metavanadate. 
In section A, three simple and sensitive extractive spectrophotometric methods 
for the assay of diltiazem hydrochloride either in pure form or in pharmaceutical 
formulations have been described. The developed methods involve formation of 
coloured chloroform extractable ion-pair complexes of the drug with bromothymol 
blue (BTB), bromophenol blue (BPB) and bromocresol green (BCG) at pH 2.8, 2.5 
and 3.5, respectively. The extracted complexes showed absorbance maxima at 415 
nm for all the three methods. Beer's law is obeyed over the concentration range 2.5-
20.0, 2.5-10.0 and 2.5-12.5 \xg ml"' with BTB, BPB and BCG, respectively. The 
methods have been applied to the determination of drug in commercial tablets and 
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capsules. Results of analyses were validated statistically and through recovery 
studies. 
Section B of third chapter describes a simple and accurate spectrophotometric 
method for determination of diltiazem hydrochloride. The drug is boiled with 
sodium metavanadate in sulphuric acid medium (11.0 M) for 20 min and the 
absorbance is measured at 750 nm. Beer's law is obeyed up to 50 |ig ml"' with RSD 
of 1.07% and molar absorptivity of 6.18 x 10^  1 mof' cm'^ The method has also 
been applied to the determination of the drug in commercial tablets and capsules. 
Fourth chapter describes two spectrophotometric methods for determination of 
amlodipine besylate in pure form and drug formulations. The details of the 
procedures are presented in two sections. 
In section A, a simple, sensitive, rapid and accurate spectro-photometric method 
for determination of amlodipine besylate based on charge-transfer complexation 
reaction of amlodipine with n acceptor p-chloranilic acid in 1,4-dioxan-chloroform 
medium has been discussed. The resulting intensely purple chloranilic acid radical 
anion possesses a characteristic absorption maximum at 540 nm. The molar 
combining ratio and optimum assay conditions were studied. Beer's law is obeyed 
in the concentration range of 100 - 600 |ig ml'^  with mean percent recovery of 
100.11 and RSD of 0.52%. The molar absorptivity and detection limit are found to 
be 0.907 X lOM mof' cm"' and 2.46 ng ml'\ respectively. The proposed method has 
been successfully applied to the determination of amlodipine besylate in marketed 
products with good accuracy and precision. The results were compared statistically 
with those given by the reported method. 
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In section B, a sensitive, selective, rapid and accurate spectrophotometric 
method for determination of amlodipine besylate in pure form and drug 
formulations has been described. The method is based on the reaction of the primary 
amino group of the drug with ninhydrin in N,N'-dimethylformamide (DMF) 
medium producing a coloured complex which absorbs maximally at 595 nm. Beer's 
law is obeyed in the concentration range of 10-60 |j,g ml"* with RSD of 0.66% and 
molar absorptivity of 6.52 x 10^  / mol"' cm"'. All variables were studied in order to 
optimize the reaction conditions. The proposed method has been successfully 
applied to the analysis of the bulk drug and its dosage forms. No interference was 
observed from common pharmaceutical adjuvants. Statistical comparison of the 
results with the reference method shows excellent agreement and indicates no 
significant difference in accuracy and precision. 
The last chapter describes a rapid, simple and sensitive visible 
spectrophotometric method for the assay of verapamil hydrochloride either in pure 
form or in pharmaceutical formulations. The method involves the oxidation of 
verapamil hydrochloride by N-bromosuccinimide in perchloric acid medium leading 
to the formation of yellow coloured product which absorbed maximally at 415 nm. 
Beer's law is obeyed in the concentration range of 10 - 200 i^g ml'' with molar 
absorptivity of 2.55 x 10^  / mol"' cm"'. The method has been successfully applied to 
the determination of the drug in commercial tablets. Statistical comparison of the 
results with those of an official method shows excellent agreement and indicates no 
significant difference in accuracy and precision. 
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CHAPTER 1 
GENERAL INTRODUCTION 
GENERAL INTRODUCTION 
In the book "Confessions of an English Opium-Eater" the man of letters Thomas De 
Quincey [1] described in a foot note the dilemma of his surgeon friend who was suffering 
from a lingering and fatal malady. Yet he had a family to support and had to continue 
working for as long as possible. Because of his professional knowledge he saw the 
necessity of reducing the daily dose of opium that he took to alleviate his pains to a 
minimimi. I now quote the words used by Thomas De Quincey. "But to do this he must 
first obtain the means of measuring the quantities of opium; not the apparent quantities as 
determined by weighing, but the virtual quantities after allowing for the alloy of varying 
amounts of impurity". With the knowledge available at the time (about 1820) De Quincey's 
friend was imable to form such an assessment. He did, however, achieve a uniform method 
of extracting the opium so as to give a fairly constant potency. 
The gradual change from the use of natural products in their entire state to either 
purified extracts from those products or to synthetic chemically-produced materials can be 
said to have been taking place between the time of Paracelsus who lived in Basel during the 
first half of the 16th century, to that of P. Ehrlich, to whom the award of a Nobel Prize in 
1909 was fitting reward for his remarkable researches and breakthrough during the first 
decade of this century. This period has been described as that leading from "Quintessence 
to Chemical and have been fascinatingly reviewed by H.J. Barber [2]. 
This transition from the quintessence to the chemical stimulated a very considerable 
amount of interest in the analysis of natural products to determine, as De Quincey had said 
one hundred years earlier, not the apparent quantities as determined by weighing but the 
virtual quantities after allowing for the alloy of impurity. 
The purpose of researches in analytical chemistry is to devise new methods of analysis 
or to improve the existing ones. Establishment of the mechanisms of various reactions and 
the formulation of the fundamental laws of Chemistry has largely been based on the results 
of chemical analysis. It has extensive applications in analysis of pharmaceuticals in drug 
formulations and body fluids, organic compounds, biochemicals, polluted water, foods, 
agriculture and in many other areas. The chemical analysis is divided into qualitative and 
quantitative analysis. The qualitative analysis deals with the detection of constituents or 
components present in compound or sample. The quantitative analysis determines the 
proportions in which the constituents or the amount of constituents are present. The greater 
part of chemical analysis is quantitative. 
The realm of analytical chemistry is widening day by day with the modem 
sophisticated instrumental techniques which made it possible to elucidate the 
microstructure of molecular species and to identify and determine the substance in the 
highest state of purity. Therefore, there have been several surveys in the past few decades 
that have summarized the recent evolution of analytical chemistry and is covered in 
modem analytical texts [3,4]. Moreover, Christian [5] has traced, in a report, the evolution 
of analytical chemistry into the 20^ century and the revolution in quantitative analysis 
using modem analytical instruments. 
Pharmaceutical analysis is one of the most promising branches of analytical chemistry. 
The chemistry dealing with pharmaceuticals reflects that, in 19th century, pharmacists 
working in their laboratories focussed on the extraction and purification of naturally 
occurring drugs. In 1876 the pharmacologist Buchheim wrote that the mission of 
pharmacology was to identify the active substance within the natural drug, to find out the 
chemical properties responsible for their action and to prepare synthetic analogs that were 
more effective [6], while the chemist took over the role of isolation and chemical 
identification of biologically active constituents from the medicinally important plants. 
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Since the drug development, introduction and pharmaceutical manufacturing entered 
their golden age. A large number of important and innovative new drugs was introduced 
day by day. Similarly, from the time a new pharmaceutical product is discovered, its 
journey through the market place can be as long as 15 years [7]. During this time, the drug 
substance will pass through many stages of development including laboratory and semi-
scale synthesis, pilot plant scale-up, efficacy and toxicology testing, clinical trials and 
finally full scale production. Therefore, it was of utmost importance to analyse the drug and 
its pharmaceutical formulations. 
The direct determination of drug in a mixture is generally performed for one or more 
purposes [8]. Either one or more active principles in a known substance are required to be 
accurately estimated for the purposes of standardization, proof of purity, commercial 
valuation, or in chemico-legal cases, in which case it may be properly called an assay, or, 
all of the essential ingredients of an unknown drug are required to be at least approximately 
separated and determined where this is possible for the purpose of obtaining some idea of 
the relative merits or demerits of the mixture and to provide a convenient and safe 
medicine to the public. 
In pharmaceutical industry, the quality of the manufactured drug and its formulations 
must be carefully controlled. Slight changes in composition or in the purity of drug itself 
can affect the therapeutic values. Therefore, it is necessary to establish the properties and 
therapeutic value of a drug before it is approved and made available in the market. 
Establishment of the permissible level of dosage of a drug requires the determination of its 
composition, toxicity and its metabolite at various stages. 
The availability of sub-standard medicines to the general public possess many 
problems, both clinically and economically. It is widely believed that such sub-standard 
preparations are readily available in many developing countries [9-14]. This may be due to 
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poor manufacturing procedures, poor storage conditions or deliberate counterfeiting of 
branded or generic products. Therefore, it is important to recognize that the drugs may 
contain impurities. These impurities may result from many sources like from raw materials 
and reagents, as reaction byproducts, and through degradation during manufacture and 
storage. Since, the impurities can have safety and efficacy implications, and are, therefore, 
the subject of considerable attention by both manufacturers and regulatory agencies. 
Impurities can be classified into three groups namely : organic, inorganic and residual 
solvents. Organic impurities may arise from starting materials, intermediates and synthetic 
by-products or from reagents and catalyst or as a consequence of degradation. Inorganic 
impurities may result froni reagents, ligands or catalysts as heavy metals or inorganic salts. 
Residual solvents are inevitable in drug substances since without solvents, purification and 
generation of the desired crystal morphology would be impossible. However, since residual 
solvents also arise in excipients and occasionally in the manufacture of drug products, it 
was decided to draft a separate guideline to address appropriate levels. A key component of 
the guideline, and a fundamental concept is qualification. Qualification is defined as the 
process of acquiring and evaluating data which establish the biological safety of the 
individual impurity or a given impurity profile at the level(s) specified. Thus, the 
pharmaceutical analyst and toxicologist must work hand in hand throughout the pre-clinical 
and clinical development programme in order to be able to set meaningful specification 
requirements. The pharmaceutical analyst must give careful thought to the analytical 
methods, especially in the development phases, Therefore, it is an important task for the 
pharmaceutical analyst to choose an analytical technique with modem instrumentation 
which provides the best solution to the problem. 
Modem approaches to pharmaceutical and biomedical analysis is due to the application 
of increasingly sophisticated methods of structural analysis like spectroscopy, isotopic 
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labeling, automated quantitative analysis, separation by chromatography and other partition 
methods. Laboratory automation through modem instruments open a new era for the study 
of minute amoimts of biochemicals up to parts-per-billion level or lower. They also 
shorten the analysis time in order to achieve high-quality routine analysis. 
The methods for determination of drugs and their formulations are divided into 
physical, chemical, physico-chemical, and biological ones. Physical methods of analysis 
involve the studying properties of substance. They include the determination of solubility, 
transparency, and the degree of turbidity; colour; density or specific gravity; melting, 
boiling and freezing points. Chemical methods of analysis for determination of drugs are 
based on chemical reactions. They include the determination of ash content, the hydrogen 
ion concentration (pH) of medium and characteristics numeral indices of oils and fats. 
Qualitative and quantitative analysis of drugs are generally carried out with respect to 
functional groups. Biological methods of analysis characterize the pharmaceutical effect of 
the drug. Biological tests are conducted on animals and less frequently on separate isolated 
organs or part of organs of animals. The effect of drug is expressed in activity units and is 
determined by comparison with the activity of a reference substance. 
The most commonly used analytical techniques in pharmaceutical analysis are 
described below. The chromatographic methods include paper chromatography, thin layer 
chromatography, column chromatography, capillary electrochromatography, high 
performance thin layer chromatography, high performance liquid chromatography, and gas 
chromatography. The electrochemical methods mainly used for this purpose are 
polarograhpy, voltammetry, and amperometry. The radiotracer techniques include mainly 
the isotopic dilution and the activation analysis. The spectroscopic techniques include 
nuclear magnetic resonance, infrared spectrophotometry, flame photometry, fluorometry, 
UV-visible spectrophotometry, derivative spectrophotometry and difference 
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Spectrophotometry. Kinetic automatic methods are good choices for drug analysis as they 
permit the sensitive, selective determination of many drugs within a few seconds with no 
sample pretreatment in many cases. Flow injection analysis is also a very fast, simple 
sensitive and inexpensive method. 
Chromatographic techniques have many applications in trace analysis. There are a 
number of analysis that could not have been accomplished in any other ways except the use 
of chromatographic techniques. High performance liquid chromatographic methods have 
been successfully applied in drug analysis and have now appeared in the dissolution 
monographs of pharmacopoeias for the assay of drug in dissolution fluids [15, 16 ]. It is 
becoming increasingly popular because of its sensitivity and specificity in multicomponent 
analysis and widely used for the identification of drugs in plasma and drug formulations 
[17-30]. 
High performance thin layer chromatographic technique is flexible enough to analyse 
different kinds of samples. It is an off-line technique whose every stage of the analysis can 
be visualized. It can be used in pharmaceuticals, biomedical and environmental analysis. 
Several drugs have been investigated by high performance thin layer chromatography in 
pharmaceutical preparations and biological fluids [31-37]. 
Capillary electrochromatography is a method in which a liquid mobile phase is driven 
through a stationary phase in a packed capillary column by the electro-osmotic flow 
generated by a large difference in potential across the column [38-41]. Capillary 
electrochromatography has been applied to the separation of several pharmaceutical 
compounds. A mixture of diastereoisomers not previously separated on a chiral HPLC 
column, was separated by capillary electrochromatography [42]. 
Flow injection analysis is a widely used analytical technique [43,44] and has several 
advantages: (1) reduced reagent consumption [45]; (2) high sampling frequency [46]; and 
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(3) safety in applying toxic reagents because the whole analysis proceeds in a closed 
system. An additional advantage observed in flow injection analysis is increased selectivity 
when the analyte is accompanied by more slowly reacting components. Flow injection 
analysis has been applied in the analysis of several pharmaceutical compounds [47-56]. 
Electrochemistry can be used at the early stage of drug researches for screening the 
pharmacological activity of a homologous series of newly synthesized molecules. There are 
several examples in the literature showing the relationship between the electrochemical 
data and the pharmacological properties of drugs [57-60]. Simple and rapid investigation 
technique such as cyclic voltammetry [61] can be advantageously applied for predicting the 
psychotic activity of the phenothiazine derivatives (from the differences in the stability of 
the cationic radical), the anti-inflammatory activity of organoselenides (from the 
differences in the oxidation potential) [58] and the anthelmintic activity of 
arylethenylpyridinium salts (from differences in the reducing potential) [59-60]. In drug 
research, electrochemical techniques may have application to drug-protein [62] and drug-
DNA binding studies [63] giving results usefril in drug bioavailability and toxicity tests, 
respectively. 
As far as the assay of drugs in a pure form is concemed, following the pharmacopoeia 
official monographs, electrochemical investigation modes are mainly concemed with 
potentiometric titration in non-aqueous media. Amperometric titrations are reported and 
few examples of polarography have been mentioned in The United States Pharmacopoeia 
since 1975. From review articles dealing with polarography and voltammetric analysis of 
drugs [64-66] it appears, however, that many drugs are electroactive. By compiling a list of 
most frequently occurring drugs (Table 1.1) and checking the electrochemical literature 
data [64-66], it was found that most of the drugs listed in Table 1.1 can be studied by 
polarography and/or voltammetry. For the investigation of drug formulations, cyclic 
voltammetry [67], potentiometric and amperometric titration, constant current and potential 
coulometry [64,65,68], ion-selective electrodes [68-71] and various voltammetric 
techniques [64-66] have been successfully applied with minor sample treatments. 
Table 1.1 
Electroactive drugs in drug formulations as the only active ingredient 
Isoniazid 
Verapamil 
Acebutalol 
Diltiazem 
Nicardipine 
Lidoflazine 
Nifedipine 
Acetaminophen 
Ampicillin 
Ascorbic acid 
Chloramphenicol 
Cyanocobalamine 
Dexamethasone 
Erythromycin 
Heparin 
Hydrocortisone 
Nitrofurantoin 
Phenoxymethylpenicillin 
Prednisolone 
Prednisone 
Retinol 
Tetracycline 
Triamcinolone 
Vincamine 
Felodipine 
Isosorbid dinitrate 
Benidipine 
Amlodipine 
Atenolol 
Nimodipine 
The use of spectroscopic methods has been made on the largest scale in the drug 
analysis. However, visible spectrophotometric methods of analysis are among the earliest 
instrumental techniques, but even today they are considered to be one of the top ranking 
methods because of their overall utility. These methods of analysis are based on measuring 
the absorption of electromagnetic radiation by coloured compounds in the visible part of 
the spectrum. If the analytes are colourless, they are converted into coloured compounds by 
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reaction with suitable reagent. In the last few decades, the technique has been extensively 
used for determination of drugs. 
UV spectrophotometric methods are simple, quick, economical, and usually do not 
require an elaborate preparation step prior to assay. However, a UV method is not adequate 
when two or more drugs with similar UV spectra are present in the sample or excipients or 
decomposition product exhibits UV interference, as is the case with dissolution testing of 
phenytoin capsules [72]. 
For spectrophotometric determinations, certain requirements must be fulfilled. The 
important one are: application of Beer's law limit, stability of the colour, sensitivity and 
selectivity of the method. Beer's law relates the absorbance with concentration by relation 
A= ebc where A is the absorbance, e is molar absorptivity, b is path length of the 
absorbing medium (expressed in cm), C is the concentration of the absorbing solute. In a 
general way, a straight line is obtained on plotting absorbance against the concentration. 
The deviation from the straight line is also observed beyond the range of applicability of 
Beer's law. 
Simple colorimetric and UV methods continue to be popular for carrying out single-
component assays on a variety of formulated products. Representative examples of some of 
the many assays that have been published are given in Table 1.2. 
Table 1.2 
Assay of drugs in drug formulations by spectrophotometric procedures 
Drug Conditions Measurement(nm) Refrences 
Ascorbic acid With l-chloro-2,4-dinitrobenzene 380 [73] 
Acetaminophen By oxidative coupling with m-cresol 640 [74] 
Menadione With sodium hydroxide 450 [75] 
Trimethoprim 
Thyroxin 
sodium 
2-methyl-l,4-
naphthoquinone 
L-dopa 
Methyl dopa 
Nalidixic acid 
Lisinopril 
Thonzylamine 
Imipramine 
Desipramine 
Amlodipine 
besylate 
Aspirin 
Astemizol 
With potassium persulphate in alkaline 355 
medium 
With nitrous acid in an ice cold bath 420 
With ethylacetoacetate and ethanolic 550 
ammonia 
With sodium hydroxide 300 
With cerium(rV) nitrate in 2M H2SO4 at 550 
80 °C 
With potassium persulphate in alkaline 
medium 
With chloranil at pH 9.5 
With dimethylbarbituric acid in 
presence of dicyclohexyl carbodiimide 
With ammonium metavanadate 
With ammonium metavanadate 
With bromothymol blue 
Chlorhexidine 
With 3-methyl-2-benzothiazolinone 
hydrazone hydrochloride 
WithNaOH 
After hydrolysis with NaOH 
With chloranilic acid 
With suprachen violet 3B 
With tropaeolin 000 
With iron (III) and 1.10-phenanthroline 
With acetic acid and N-
bromosuccinimide 
With HCl and celestine blue 
With Folin-Ciocalteau reagent and 
NaOH 
With glycine buffer and azocarmine G 
With alizarin yellow G 
390 
630 
10 
[76] 
[77] 
[78] 
[79] 
[80] 
[81] 
346 
492 
618 
618 
405 
[82] 
[83] 
[84] 
[84] 
[85] 
[85] 
456 
302 
540 
590 
500 
515 
520 
540 
720 
540 
405 
[86] 
[87] 
[88] 
[89] 
[89] 
[89] 
[90] 
[90] 
[90] 
[90] 
[91] 
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gluconate 
Cisapride 
Diclofenac 
sodium 
Flurazepam 
Loperamide 
hydrochloride 
Loratadine 
Mefenamic acid 
Niclosamide 
Oxprenolol 
Phenylephrine 
Terfenadine 
Verapamil 
hydrochloride 
Benidipine 
hydrochloride 
Nitrendipine 
With chromotropic acid 
With phloroglucinol 
WithN-(l-naphthyl) ethylene-diamine 
dihydrochloride 
In Tris buffer 
With p-dimethylaminocinnamaldehyde 
In HCl solution 
Between pH 6 and pH 0 
With bromothymol blue 
With bromophenol blue 
With naphthol blue black B 
With bromophenol blue 
With p-dimethylaminocirmamaldehyde 
With zinc and p-benzoquinone 
With Ce(IV) in H2SO4 
With nitrating agent 
With potassium dichromate 
With chromotrope 2B 
With chromotrope 2R 
With bromocresol green 
With bromophenol blue 
With thymol blue 
With zinc and HCl, followed by 
530 
450 
540 
284,305 
538 
230 
225 
414 
415 
627 
415 
665 
506 
480 
410 
370 
530 
546 
408.5 
404 
570 
555 
[92] 
[92] 
[92] 
[93] 
[94] 
[95] 
[95] 
[96] 
[96] 
[96] 
[97] 
[94] 
[98] 
[99] 
[100] 
[101] 
[102] 
[102] 
[103] 
[103] 
[103] 
[104] 
Atenolol 
diazotisation and coupling with N-(l-
naphthyl) ethylenediamine-2HCl 
With chloranilic acid 534 [105] 
Timolol 
Sodium 
Penicillin G 
Gentamicin 
With chloranilic acid 
With azure A 
With ninhydrin 
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530 [105] 
660 [106] 
400 [107] 
Colorimetric methods based on charge-transfer reaction of certain n-acceptors have 
been successfully utilized in pharmaceutical analysis. The n-acceptors such as p-chloranilic 
acid, dichlorophenyl-indophenol and 2,3-dichloro 5,6-dicyano p-benzoquinone have been 
used to carry out the spectrophotometric assay of certain cardiovascular drugs: 
carbochromen hydrocloride, verapamil hydrochloride, acebutalol hydrochloride, carazolol 
and propranolol hydrochloride [108]. Spectrophotometric procedures have been presented 
for determination of two commonly used antidepressant drugs, fluoxetine and sertraline 
hydrochloride. The methods are based on charge-transfer complexation reaction of these 
drugs with either 7i-acceptors, chloranil and 2,3-dichloro-5,6-dicyano p-benzoquinone or o 
acceptor iodine [109]. The cardiovascular drugs, nifedipine and diltiazem hydrochloride 
have also been assayed in dosage forms by charge-transfer complexation reactions with 
chloranil [110], chloranilic acid and 2,3-dichloro-5,6-dicyano p-benzoquinone [111], 
respectively. 
Acid dyes, solochrome dark blue, solochrome black T, bromothymol blue, 
bromophenol blue, bromocresol green, bromocresol purple, sunset yellow and indigo-
carmine form ion-pair complexes with basic drugs which were quantitatively extracted into 
chloroform. Colorimetric methods based on dye pairing continue to be important and have 
been used to assay such compoimds as amlodipine besylate [112-114], verapamil 
hydrochloride [115], phenothiazine derivatives [116] and famotidine [117] in drug 
formulations. 
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Derivative spectrophotometry presents a greater selectivity and offers a convenient 
solution to the problem of resolving spectral overlap in the analysis of multicomponent 
systems [118-131]. Peak to peak and base line measurements and zero crossing 
measurements are the most common techniques used to prepare analytical working curves. 
The zero-crossing method involves the measurement of the absolute value of the total 
derivatives spectrum at an abscissa value (wavelength) corresponding to the zero-crossing 
point of the derivatives spectrum of the interfering component. At this wavelength, the 
amplitude of the derivative signal of one of the two components passes through zero, 
measurements of the value of the derivative spectrum of a mixture, made at the zero-
crossing point of the derivative spectrum of one of the components is, therefore, a function 
only of the concentration of other component [132]. O'Haver [133] discussed the potential 
of the derivative spectrophotometry in clinical chemistry. Fell [134] has demonstrated the 
possibilities offered by this technique for the analysis of pharmaceutical formulations. 
Second derivative approaches have been described for antidepressants clomipramine 
[135] and imiprmine [136] hydrochlorides, the flavanoids chrysin and quercetin [137,138] 
and the anticholinergic homoatropine hydrobromide [139]. A second-derivative procedure 
also has been used to measure 3-chloro-N-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4-amine-
1,2-naphthoquinone in the presence of its degradation product which was reported not to 
interfere [140]. In the case of esculine and routine, not only have the first and second-
derivative spectra been used but also higher-derivative curves [141]. Differences in the 
measurement accuracy using these approaches are considered. Other applications of 
derivative spectrophotometry includes its use to measure acyclovir and diloxanide furoate 
in the presence of degradation products and impurities [142] as well as to determine 
amiloride [143], benazepril hydrochloride [144], enalapril maleate [135], and metoprolol 
and propranolol [136] in combination products containing hydrochlorothiazide. 
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Difference spectrophotometry has been proved particularly useful in the determination 
of medicinal substances by eliminating specific interference from degradation products, co-
formulated drugs and also the non-specific irrelevant absorption from the formulation 
matrix. Its advantages for selective analysis have been described by several workers [145-
149]. The technique involves the reproducible alteration of the spectral properties of the 
absorbance difference between two solutions, provided that the absorbance of the other 
absorbing substances is not affected by the reagents used to alter the spectral properties. 
Simple aqueous acids, alkalis and buffers are most frequently used for inducing spectral 
alteration since many drugs are weak acids or bases whose state of ionization and 
absorptivity depend on the pH of the solution [150]. 
Kinetic methods are good choices for drug analysis as they permit the sensitive and 
selective determination of many drugs within a few seconds with no sample pretreatment in 
many cases. They seem to be more attractive and superior to the other colorimetric 
methods due to the formation of unstable colours in some of these colorimetric ones. 
Moreover, the instrumentation required is generally very simple. The principles and 
applications of the kinetic methods have been reviewed in papers [151,152] and books 
[153,154]. Essentially, kinetic methods rely on measurements of concentration changes 
(detected via signal changes in a reactant (which may be the analyte itself) with time after 
the sample and reagents have been mixed. The sample and reagent can be mixed manually 
or automatically. Only slow enough reactions tolerate manual mixing and, even so, they 
may be better handled automatically, not only to obtain more rapid and reproducible 
results, but also to increase the reaction rate in some cases. Kinetic automatic techniques 
are generally based on open systems, among the most popular of which are stopped flow 
(SF) system and the continuous addition of reagent (CAR) technique [155-158]. Several 
drugs have been determined by using CAR technique with photometric [159,160] and 
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fluorimetric [161] detectiori. These techniques are mandatory for fast reactions but can also 
be extended to slow reactions. In both cases, the Icinetic curve (variation of the analytical 
signal with time) can be recorded immediately. The slope of the straight initial portion of 
the kinetic curve gives the reaction rate, which is proportional to the analyte concentration 
(initial-rate method). The fixed-time method, also frequently used to derive such a 
concentration, involves measuring the signal (the value of which depends on the analyte 
concentration) at a preset time. 
These determinations can be implemented by using combinations of the SF technique 
with (a) fluorescence polarization immunoassay (FPIA), (b) micelle-stablized room-
temperature phosphorimetry (MSRTP) and (c) a sensitized energy-transfer fluorescence 
reaction, among other, all are novel strategies which have so far yielded excellent results in 
drug analysis. On the other hand, the CAR technique has been extended to 
chemiluminescence (CL) reactions as CAR chemiluminescene spectrometry (CARCL), a 
new approach which have proved outstanding for the analysis of drugs and other 
substances of analytical interest. 
The use of kineitc methods [162-165] in micellar media is another recent approach to 
kinetic-based determinations that has proved useful in drug analysis. Micelles increase the 
reaction rate (through micellar catalysis) and may additionally increase the sensitivity and 
selectivity for the analyte. On the other hand, new kinetic chemometric (kinetometric) 
approaches such as the Kalman filter have been developed and applied to the simultaneous 
determination of various compounds of pharmaceutical interest. 
Before an analytical method can be used for routine analysis, it must first be 
demonstrated that the method fulfils certain performance criteria. When this has been 
documented, the method is said to be validated. The parameters that require validation and 
the approach adopted for each particular case are dependent on: (a) the purpose of the 
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method, and (b) the sample matrix. With respect to the purpose of the method, one should 
consider for example whether it is to be applied to the determination of a major or minor 
component, or for evaluation of performance characteristics (e.g. dissolution test for a solid 
dosage form) and whether the test will then be used to support a release specification or a 
stability study. 
In the field of drug analysis, it is very clear that the definitions cover the entire field of 
analytical chemistry from bioanalysis to substance and product analysis. There are a 
nimiber of definitions [166] given by several intemational organizations which are listed 
below: 
Validation of analytical methods - international definitions 
Organization 
lUPAC 
ILAC 
WELAC 
ICH 
ISO 
Applicability 
Worldwide 
Worldwide 
Europe 
Europe, Japan, USA 
Worldwide 
Remarks 
Only pharmaceutical products 
Lacks definitions of 
selectivity and specificity 
Abbreviations: lUPAC, Intemational Union of Pure and Applied Chemistry; ILAC, 
Intemational Laboratory Accreditation Conference; WELAC, Western European 
Laboratory Accreditation Cooperation; ICH, Intemational Conference on Harmonization; 
ISO, Intemational Organization for Standardization. 
In the last few years harmonization efforts have been rather intensive in the 
pharmaceutical field and also for the validation process. Unfortunately, for analytical 
chemists, this effort from the regulatory bodies side as exemplified by the ICH, has only 
focussed on validation of analytical procedures used for the control of substances and 
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formulations. Similar requirements have, however, also to be applied for analysis of drugs 
in body fluids. Most of the definitions recommended by the IGH are concordant with those 
of other organizations such as lUPAC, ILAC and WELAC. Terms and definitions should 
have the same meaning all over the world, whatever kind of analysis is performed. 
Method validation is an important component in determining the reliability and 
reproducibility of a bioanalytical method, and is a requirement of any regulatory 
submission [167]. The policy of Food and Drug Administration (USA) states that for each 
analytical method used to quantitate drug concentrations from biological fluids, specific 
analytical parameters must be determined with respect to accuracy, linearity, precision, 
sensitivity, specificity and recovery. 
The overall validation strategy consists of four components, which are the 
prevalidation, validation proper, study proper and statistical analysis. These components 
constitute the platform upon which to evaluate the reliability and ruggedness of an 
analytical method. 
Prevalidation 
Before validation proper can be contemplated, an authenticated analytical reference 
standard must be available to prepare solutions of known concentrations. This standard 
should be of a known form, e.g. fi-ee base or salt and of known purity, if used over a time, 
should be monitored to ensure no decomposition or contamination has taken place. 
Prevalidation provides the analyst an opportunity to obtain some practical experience with 
the method and helps to identify the optimum experimental conditions. It is also 
recommended that the following studies be conducted prior to initiating the validation 
proper. The appropriate measurements of concentration changes (detected via signal 
changes) in a reactant (which may be the analyte itself) with time after the sample and 
reagents have been mixed. The optimum standard curve range and the number of 
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calibrators should be established. The appropriate regression model, which best fits the data 
is then selected. The extraction scheme and its recovery should be optimized to give insight 
into the limit of quantitation and to help determine if the extraction procedure is 
reproducible. 
Validation proper 
The fundamental parameters for assessing the reliability and over all performance of an 
analytical method which should be addressed in a validation exercise include: analyte 
stability, selectivity/specificity, limits of detection and quantitation, accuracy, precision, 
linearity and recovery. 
Analyte stability 
Published literature should be investigated, or laboratory tests should be conducted to 
determine whether pure analyte and /or solutions of the analyte (e.g drug) are stable under 
normal laboratory conditions of heat, humidity, light and air exposure. 
Accuracy 
A reasonable definition is provided in the United States pharmacopoeia XXII [168] : 
"The accuracy of the analytical method is the closeness of test results obtained by that 
method to the true value." Some details of how accuracy should be determined are 
provided in The USP XXII and Committee for Proprietary Medicinal Product (CPMP) 
guidelines [168,169]. 
In bulk drug analysis, the api^oach adopted depends on the assay method to be 
adopted. For titrations the expected equivalence point may be calculated on theoretical 
grounds, taking into account the number of titratable functions in the analyte and the 
molecular weight, but it is reconunended that this should then be verified by carrying out 
the intended titration procedure on a well characterized reference standard. 
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For light absorption assays based on specific absorbance values, the validation would 
require that this value be well selected. It should be noted that these values for closely 
related compounds may vary considerably, so it would also be appropriate to demonstrate 
that this is not significantly influenced by the presence of likely impurities at their intended 
maximum limits. For chromatographic assays, the mass balance approach of Krischbaum 
et al. is recommended [170]. This is based on the comparison of total peak response with 
and without the chromatographic column in place; a variance of not more than ± 2% should 
normally be achieved. 
Precision 
This describes the closeness of replicate determinations of an analyte by an assay 
procedure. Precision can be fiirther sub-divided into within day precision, intra-assay 
precision or repeatability (which is an assessment of precision during a single analytical 
run) and between-day precision, Inter-assay precision or reproducibility (which shows the 
variation of precision with time and may also include different analytical staff, equipment 
and reagents). 
Intermediate Precision Conditions 
The M-Factor for different intermediate precision conditions [M=l, 2 or 3] are : 
(a) M= 1 where only one of the three factors ( operator, equipment or time ) is different or 
where the instrument is recalibrated between successive determinations, (b) M=2 where 
two of the three factors are different, and (c) M=3 where all the three factors are different 
between successive determinations. 
Linearity 
A reasonable definition is provided in CPMP Guidelines [169]: "The linearity of a 
test procedure is its ability (within a given range) to produce results which are directly 
proportional to the concentration of analyte in the sample". 
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Limit of detection (LOD)/ quantitation (LOQ) 
Limit of detection (LOD) is a parameter of limit tests and may be defined as the 
smallest quantity of analyte which may be expected to produce a response which is 
significantly different from that of a blank. 
Limit of quantitation (LOQ) is a parameter of determination test and may be defined as 
the smallest quantity of analyte which can be determined with acceptable accuracy and 
precision. 
According to lUPAC [171] for spectrochemical methods these values may be 
determined for the smallest concentration (ci) or amount (qi) fi-om: ci(qi) = kSe/S, where k 
is a constant, SB is the standard deviation of analytcial blank signal, and S is the slope of 
response versus concentration curve (slope sensitivity). Recommended values for k are: for 
LOD, k=3; and for LOQ , k = 10. Justification of these values has been provided by Long 
and Winefordner[ 172] and by the Analytical Methods Committee [173]. For this to be 
used in practice then, requires determination of the value of SB, which is related to baseline 
noise. For spectrochemical methods this is not a problem as the analyst can conduct a series 
of absorbance determinations with blank solutions, using instrumental conditions intended 
for sample determinations. The standard deviation may then be calculated. 
Selectivity and Specificity 
One of the key definitions for analytical chemist is, without doubt, selectivity. This can 
be considered as the hallmark of the analyst. If it is not clear about the effect of potential 
interferences in the method, all other attributes such as accuracy, precision, linearity, etc. 
are meaningless. The definition by WELAC [174] clearly states that selectivity of a method 
refers to the extent to which it can determine particular analyte (s) in a complex mixture 
without interference from other components in the mixture. A method which is perfectly 
selective for an analyte or group of anlayte is said to be specific. A clear distinction 
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between the terms specific and selective has been made by Christian in his well known-
treatise. Analytical Chemistry [175]. He stated that a specific reaction or test is one that 
occurs only with the substance of interest, while a selective reaction or test is one that can 
occur with other substances but exhibits a degree of preference for the substance of 
interest. Few reactions are specific but may exhibit selectivity. 
To visualize the difference between specificity and selectivity, a graphical 
representation is given in Fig. 1.1 Selectivity is something that can be graded or scaled but 
specificity is an absolute characteristic. 
100 4 % 
Signal 
from analyte 
alone 
(a) 
Non-specific 
Specific 
Not to be "Scaled" or graded 
100 
Signal 
from analyte 
alone 
Degree of selectivity (%) 100 
Fig. 1.1. Graphical demonstration of selectivity and specificity. The percentage of the 
measured signal attributable to the analyte alone (on the Y-axis) is given as a function of 
the degree of selectivity (b). A perfectly selective method is said to be specific (a). 
Study Proper and Statistical Analysis 
Daily standard curves are generated to determine the sample concentrations. The 
quality control sample sequence is carefully monitored for systematic errors. For each 
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standard curve, the slope, intercept, variance and correlation coefficient are reported. From 
the data generated, specific analytical parameters are reported including linearity, accuracy, 
precision, sensitivity and recovery. Acceptance of the assay results is determined by 
monitoring the quality control results. If the concentrations are vAthin the control chart's 
confidence limits, established during the method validation, the data are considered valid. 
Upon completing a study proper and accepting the analytical runs, the quality control 
results are incorporated into their respective databases to update their confidence limits. 
As part of an on-going study looking at the quality of selected pharmaceuticals in 
developing countries, it vs'as necessary to assay the pharmaceutical substances in all kinds 
of formulations. It is also necessary to establish methods, which are simple, sensitive, 
accurate and rapid and can be used for routine analysis in the laboratories of limited 
resources in these countries. 
This thesis deals with the spectrophotometric determination of some antianginal drugs 
with special reference to calcium channel blockers namely nifedipine, diltiazem 
hydrochloride, amlodipine besylate and verapamil hydrochloride in pharmaceutical 
formulations. 
ANTIANGINALS 
Angina pectoris is a symptom of ischaemic heart disease [176]. Drugs used in angina 
pectoris are those that reduce cardiac work and myocardial oxygen need by (a) unloading 
the heart (b) dilating capacitance and resistance vessels (c) dilating coronary arteries and 
(d) blocking P-adrenoceptors. Anginal pain occurs when the coronary blood flow is 
insufficient to meet the heart's metabolic requirements, it can be counteracted by drugs that 
either improve myocardial perfusion or reduce the metabolic demand, or both. Several 
antianginal drugs are available for treatment of angina. These include (a) Organic nitrates 
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(b) beta adrenergic blockers (c) calcium channel blockers (d) potassium channel activators 
and (e) antiplatelet drugs. 
Calcium channel blockers 
Calcium chaimel blockers are heterogeneous group of drugs whose main 
pharmacological effect is to prevent or slow the entry of Ca into cells via specialized 
calcium channels. Other names used for this class of drugs include calcium entry blockers, 
calcium antagonists and slow channel blockers, since the entry of calcium into cells is 
slower than sodium entry after stimulation. 
Ca^"*" enters cells through specialized pores in the membrane wall called calcium 
channels. Some charmels are activated by membrane depolarization (voltage operated) and 
others by activated receptors for neurotransmitters and/or sundary hormones and tissue 
factors (receptor-operated). Calcium channel blockers describe Ca^ "^  entry in both the 
voltage-operated and receptor operated chaimels, but the voltage-operated channel is the 
more sensitive to drug blockade. 
Three different calcium chaimels have been characterized. L-(long opening) and T-
(transient) chaimels have been found in neurosecretory cells and cardiac, smooth and 
skeletal muscle cells, and N-(neuronal) channels have been located only in neurons. Each 
channel type has its ovra characteristic activation and inactivation voltage ranges, channel 
conductance, sensitivity to blockade by organic and inorganic compounds, etc, such that 
each has a unique pharmacoresponsive profile. Also, calcium channel blockers exhibit both 
frequency-and voltage-dependence in their ability to block Ca^ "^  movements. Verapamil, 
for example, binds to open channel and hence selects cells that are stimulated frequently; in 
contrast, dihydropyridines bind more strongly to inactivated channels and hence show little 
frequency-dependence. However, all calcium channel blockers are voltage-dependent in 
that they are much better blockers when the tissue is depolarized. None of the calcium 
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channel blockers actually occlude the channel directly but rather act at allosteric sites on 
channel proteins to evoke conformational changes that cause occulsion. Calcium channel 
blockers have been approved for the oral treatment of variant (vasospastic) and chronic 
stable and unstable exertional angina pectoris. They are useful in the therapy of these 
diseases for three reasons: (a) they directly dilate coronary arteries and increase myocardial 
blood flow (b) they decrease myocardial oxygen demand by peripheral arteriolar dilation 
which increases afterload and (c) they exert negative chronotopic and inotropic actions 
which also decreases oxygen demand. 
The nine calcium channel blockers that have been approved for clinical use have 
diverse chemical structures. Five classes of compoimds have been examined [177]: (a) 
phenylalkylamines (b) dihydropyridines (c) benzothiazepines (d) diphenylpiperazines and 
(e) diarylaminopropylamine. 
At present, verapamil hydrochloride (a phenylalkyl amine); diltiazem hydrochloride (a 
benzothiazepine); nifedipine, amlodipine besylate, nicardipine, isradipine, felodipine and 
nimodipine (dihydropyridines); and bepridil (a diarylaminopropylamine ether) are 
approved for clinical use. 
Nifedipine 
Nifedipine, i.e. dimethyl l,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl) pyridine-3,5 
dicarboxylate js the prototype compound of dihydropyridine class of calcium channel 
blockers with peripheral and coronary vasodilator properties. It reduces peripheral 
resistance, afterload and blood pressure. It is given by mouth in the management of 
hypertension and angina pectroris. In human, nifedifine is rapidly metabolized by oxidative 
mechanisms to dehydronifedipine which is further metabolized to more polar compounds 
[178-181] and their structures are given below: 
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H3COOC COOCH, 
H j C O O C . ^ - ; ^ ^ COOCH3 
(C) 
H3COOC COOCH3 
H 3 C r ^ N ' ^ C H 3 
(B) 
H3C 
H3C 
CHH2COOC COOCH3 
where (A) nifedipine, (B) dehydronifedipine, (c) nitroso-analogue of dehydronifedipine 
and (D) nisoldipine. 
Nifedipine is highly sensitive to photo-oxidation, changing in colour from yellow to 
brown upon exposure to light [182]. Nifedipine photodegradation products have a little or 
no pharmacological activity [183,184]. Several studies in the past have been conducted to 
determine the photostability of nifedipine in solution and in the solid state, including 
photostablity of pulverized nifedipine tablet powders [185-187]. 
Official USP guidelines for nifedipine capsules state that the measured amount of 
nifedipine in commercial product be within 90-110% of the labelled quantity [188]. 
Manufacturers of nifedipine product utilize light resistant coatings and / or packaging to 
minimize photodegradation of oral nifedipine preparations from inadvertent light exposure. 
Few queintitative studies on the light transmissive properties of different light protective 
tablet film coatings or protective packaging have been done [189]. Thus, differences in 
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degree of light protection may exist between different brands and/ or formulation types of 
nifedipine products. 
Diltiazem hydrochloride 
Diltiazem, (+)-5-[2-(dimethylamino)ethyl]-cis,2,3-dihydro-3-hydroxy-2-(p-methoxy-
phenyl)-l,5-benzothiazepine-4(5H)-one acetate monohydrochloride developed in Japan in 
the early 1970's [190] is a benzothiazepine calcium channel blocking agent and its 
structure is shown as: 
.OCH3 
• HCl 
CH3 
C H 2 - C H 2 - N ^ 
^ C H 3 
It is a peripheral and coronary vasodilator with limited negative inotropic activity but 
its vasodilator properties are less marked than those of the dihydropyridine calcium channel 
blocker (nifedipine). Unlike nifedipine, diltiazem hydrochloride inhibits cardiac 
conduction, particularly at the sino-atrial and atrioventricular nodes. It is used in the 
management of angina pectoris and hypertension. 
Amlodipine besylate 
Amlodipine besylate is a dihydropyridine calcium channel blocking agent and 
chemically it is 3-ethyl 5-methyl2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-l,4-dihydro-
6-methyl pyridine-3,5-dicarboxylate monobenzene sulphonate. The structure of amlodipine 
is shown as: 
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H 
H,c^ N^ CH2OCH2CH2NH2 
COOC2H5 
It is used in the management of hypertension and angina pectoris. Its actions are similar to 
those of nifedipine. 
Verapamil hydrochloride 
Verapamil, 5-[N-(3,4-dimethoxyphenylethyl) methyIamino]-2-(3,4-dimethoxyphenyl)-
2-isopropyl valeronitrile monohydrochioride is a calcium channel blocker belonging to the 
phenylalkylamine class of compound and its structure is shown as : 
OCH, HCl 
OCH3 
It is a vasodilator primarily indicated for anginas and arrhythmias. Verapamil is less 
potent vasodilator in vivo than are the dihydropyridines. 
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CHAPTER 2 
KINETIC SPECTROPHOTOMETRIC 
METHOD FOR DETERMINATION OF NIFEDIPINE 
IN PURE FORM AND PHARMACEUTICAL 
PREPARATIONS 
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INTRODUCTION 
Nifedipine, i.e. dimethyl-l,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl) pyridine-3,5 
dicarboxylate is an important calcium antagonist [1] which selectively dilates comonary 
arteries with a little or no effect upon other blood vessels. Therefore, nifedipine is 
frequently used as coronary vasodilator in the treatment of angina pectoris. It is a sensitive 
substance which decomposes in day light to give the 4-(2-nitrosophenyl)-pyridine 
homologue and under UV light to give the oxidation product, 4-(2-nitrophenyl)-pyridine 
homologue [2]. 
UV light 
HjCOOC 
H a C - ^ N ^ ^ C H 
H3COOC 
H3C - j ^ 
This process involves the reduction of aromatic nitro group to nitroso group and /or the 
oxidation of the dihydropyridine ring to pyridine ring. These unfavourable physical and 
pharmacokinetic characteristics are related to the redox processes on the dihydropyridine 
moiety. From its electrochemical reduction point of view, nifedipine has been studied using 
mercury electrode[3-5]. Nifedipine has also been determined by linear sweep and cyclic 
voltammetry [6,7]. The method was based on the reduction and oxidation of the drug at 
glassy carbon electrode. 
Thin layer chromatoraphy was used for qualitative analysis of nifedipine in commercial 
dosage forms and then quantitative estimation was done either by chromatographic-
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spectrophotometric method or by gas chromatography coupled with mass spectrometry[8]. 
High performance liquid chromatographic methods[9-17] were widely used for 
identification of nifedipine and its photodegradation products. Reversed phase HPLC 
methods have also been discussed for its determination in human plasma and serum [18-
19]. Nifedipine was also determined by a number of gas chromatographic methods [20-25]. 
The determination of drugs in dosage forms was achieved by somewhat less expensive 
techniques such as spectrophotometry. Nifedipine was estimated iiv capsules and tablets by 
UV-visible spectrophotometry at 340 nm [26]. It was also determined in pharmaceuticals 
by spectrophotometry based on measuring yellow colour produced by reaction of the 
methanolic solution of the drug with 4-dimethylaminobenzaldehyde in H3PO4 at 380 nm 
[27]. Sastry et al. [28] have developed a spectrophotometric method for its determination. 
The method involved the formation of a blue complex on treatment with Folin-Ciocalteau 
reagent and subsequent determination was done at 600 nm. Karadi et al. [29] have 
recommended the assay of nifedipine after converting it to its reduced form with zinc 
granules and 3M hydrochloric acid. The amino group in reduced nifedipine formed schiff s 
base with 3,4,5-trimethoxybenzaldehyde. The absorbance was measured at 365 nm and 
Beer's law was obeyed over the concentration range of 10-70 fig ml"'. Another 
spectrophotometric method [30] was described for its assay based on the formation of 
charge-transfer complex with chloranil. Nifedipine and atenolol in combined preparations 
have been determined spectrophotometrically using the first derivative spectra of their 
solutions in methanol [31] while quantification of nifedipine alone was done using second 
order derivative spectra of the compound in 0.1 M HCl [32]. Simultaneous determination 
[33] of nifedipine and acebutalol hydrochloride in pharmaceutical preparations has been 
done by first derivative spectrophotometry at 400 and 352 nm, respectively. Beer's law 
was obeyed in the range of 4-12 jig ml"' for nifedipine. Another first derivative 
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spectrophotometric method has also been described [34] for simultaneous determination of 
nifedipine and mefruside. The first derivative method depends on the measurement of the 
derivative amplitude at 390 and 282nm for determination of nifedipine and mefruside, 
respectively. 
This chapter describes a kinetic spectrophotometric method for determination of 
nifedipine in pure form and pharmaceutical preparations. 
EXPERIMENTAL 
Spectronic 200"^  spectrophotometer (Milton Roy Co., USA) was used to record the 
absorbance. 
All chemicals used were of analytical or pharmaceutical grade. A 0.1 % nifedipine (J.B. 
Chemicals and Pharmaceuticals Ltd., India) solution was prepared in methanol and kept in 
dark to avoid contact with' light. A 0.1% potassium permanganate was freshly prepared in 
doubly distilled water. 
Procedure for determination of nifedipine 
Aliquots of 0.18-0.44 ml of the standard solution of nifedipine were pipetted into a series 
of 10 ml standard volumetric flasks. One ml of 0.1% potassium permanganate was added in 
each and then diluted to volume with doubly distilled water at 30±1 °C. After mixing, 
reaction mixtvire was immediately transferred to spectrophotometric cell and the 
absorbance was recorded as a ftinction of time at 530 nm. The initial rate of the reaction (v) 
at different concentrations was obtained from the slope of the tangent to the absorbance-
time curve. The calibration curve was obtained by plotting logarithm of the initial rate of 
the reaction (log v) vs. logarithm of the concentration of nifedipine (log C). 
Determination of nifedipine in pharmaceutical preparations 
Twenty tablets were weighed accurately, ground to a powder and mixed. An aliquot 
equivalent to 50 mg of nifedipine was stirred with 20 ml of methanol, let stand for 10 min, 
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the residue filtered on a Whatman No. 42 paper and washed with methanol. The filtrate and 
washing were diluted to volume in a 50 ml volumetric flask and subjected to the procedure 
for determination. 
RESULTS AND DISCUSSION 
Potassium permanganate is an oxidizing agent having an absorption maximum at 530 
nm. The oxidation of nifedipine by potassium permanganate at neutral pH was followed 
spectrophotometrically by measuring the decrease in absorbance at 530 nm. Fig. 2.1 and 
2.2 show the absorbance-time curves of varying concentration of nifedipine at a fixed 
KMn04 concentration and of varying KMn04 concentration at a fixed nifedipine 
concentration, respectively. The slope of the tangent to the absorbance-time curve is used 
as a measure of the initial rate of the reaction. The rate at which permanganate is consumed 
obeys first-order rate when nifedipine is in excess. Hence, the order of the reaction with 
respect to permanganate is one. The order with respect to nifedipine is found to be two, the 
over all order being three. The following kinetic equation is proposed for nifedipine-
potassium permanganate reaction: 
d[KMn04] 
dt 
= k [Nifedipine]^ [KMn04] 
The oxidation of nifedipine has been studied earlier [35] and therefore, its oxidation by 
dilute aqueous KMn04 at pH 7.2±0.2 may proceed as shovra in the following equation: 
Cl (1 
+ MT04 
+ HO-MT-O 
H 
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1.15 n 
16 
Time, min 
1 I I I I r 
20 24 
Fig. 2.1. Absorbance - time curves:_i<Mn04,6.32 x 
IC'^M and nifedipine,(a) 5.197 x 10 M; (b) 5.775 
1 0 - ' M ; (C) 7.219 X 10 ^M; (d) 8.663 x 10 ^M; 
(e) 11.550 X 10"^M; (f) 12.705 x lO'^M. 
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The disproportionation between immediate oxidation states of manganese results 
finally in the formation of Mn02. However, no precipitation of Mn02 has been observed 
under study time period. 
Calibration curve (Fig. 2.3) constructed by plotting logarithm of initial reaction rate 
(log v) vs. logarithm of nifedipine concentration (log C) showed a linear relationship over 
nifedipine concentration range of 18-44 ^g ml"'. The data used for constructing the 
calibration graph are given in Table 2.1. The linear regression analysis shows that log v = 
6.086+1.960 log C with correlation coefficient, r = 0.998. 
The precision of the proposed kinetic method was checked by ten replicate 
determinations of 0.25 mg nifedipine. Relative standard deviation and mean percent 
recovery were 1.5 and 100.2%, respectively. Results are summarized in Table 2.2. The 
validity of the proposed kinetic method was checked by applying the standard addition 
method and the results are reported in Table 2.3. 
A study of interference of some compounds was made during determination of 0.25 mg 
nifedipine. It was found that starch and sucrose could be tolerated with a maximum amount 
of 68.5 and 16.2 mg, respectively. 
The proposed method has been applied to the determination of nifedipine in 
pharmaceutical preparations. The results obtained by this method (Table 2.4) were foimd to 
be in good agreement with those obtained by BP method [36]. 
The calculated t-test values did not exceed the theoretical value which indicates the 
absence of any significant difference in terms of precision and accuracy. 
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Table 2.1 
Data used for constructing the calibration graph for nifedipine 
Concentration of nifedipine, C log C Initial rate of reaction, v logv 
(moir^) (moir^) (moir 'min- ') (moir 'min- ') 
5.197x10'^ 
5.775 X 10'^ 
7.219 X 10'^ 
8.663x10"^ 
11.550x10"^ 
12.705 X 10"^ 
4.284 
4.238 
4.141 
4.062 
3.937 
3.896 
4.888x10"^ 
6.000x10"^ 
9.387x10"^ 
13.333 X 10"^  
23.428x10"^ 
27.878 X 10"^  
-2.311 
- 2.222 
- 2.027 
- 1.875 
-1.630 
-1.555 
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Table 2.2 
Precision testing of the proposed kinetic method 
Sample No. Initial reaction rate, v Amount of nifedipine found 
(mol r ' min"') (^g per 10 ml) 
254.8 
248.5 
246.4 
250.0 
249.4 
255.8 
255.1 
245.7 
247.1 
252.9 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
9.60x10"^ 
9.20x10"^ 
9.13x10"^ 
9.38x10-3 
9.33 X 10"^  
9.75 X 10-3 
9.91 X 10-3 
9.00x10-3 
9.14x10-3 
9.56x10-3 
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Table 2.3 
Determination of nifedipine in pharmaceutical preparations by standard addition 
method 
Preparation^ 
Nicardia Retard-10 
Adalat Retard-10 
Calciguard-10 
Amount taken 
(^g ml-') 
10.0 
10.0 
20.0 
10.0 
10.0 
20.0 
10.0 
10.0 
20.0 
Amount added 
(^g ml-') 
15.0 
20.0 
20.0 
15.0 
20.0 
20.0 
15.0 
20.0 
20.0 
Total amount 
found 
(^g ml-')" 
24.92 
30.01 
40.14 
25.05 
30.01 
39.98 
25.32 
29.84 
40.10 
Recovery 
(%) 
99.7 
100.0 
100.4 
100.2 
100.0 
100.0 
101.3 
99.5 
100.3 
RSD 
0.3 
0.6 
0.3 
0.6 
0.6 
0.6 
1.1 
0.5 
1.2 
^Drug samples are in tablet form. 
"Three independent analyses. 
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Table 2. 4 
Determination of nifedipine in dosage forms by the proposed kinetic method 
and reference method 
Preparation 
Nicardia Retard-10 
Adalat Retard-10 
Calciguard-10 
Nominal 
Composition 
(mg) 
10 
10 
10 
Kinetic method 
Recovery RSD 
(%) {%f 
99.9 
100.3 
100.6 
0.6 
0.9 
1.1 
/^  
0.536 
0.604 
1.166 
Reference 
Recovery 
(%) 
100.0 
100.0 
100.1 
method [36] 
RSD r" 
{%f 
0.1 
0.1 
0.1 
0.485 
0.485 
1.579 
^Five independent analyses. 
''r-value at 95% confidence level is 2.776. 
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CHAPTER 3 
ANALYSIS OFDILTIAZEMHYDROCHLORIDE 
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INTRODUCTION 
Diltiazem,(+)-5-[2-(dimethylamino)ethyl]-cis,2,3-dihydro-3-hydroxy-2-(p-methoxyphe-
nyl)-l,5-benzothiazepin-4(5H)-one acetate monohydrochloride, is an important coronary 
vasodilator drug of the calcium channel-blocker, used in the therapy of heart disease and 
hypertension [1]. The compound also exhibits weak negative inotropic and chronotropic 
actions as well as a weak hypotensive activity [2-4]. The drug and its tablet formulations 
are official in The United States Pharmacopoeia XXIII [5], British Pharmacopoeia [6], and 
Indian Pharmacopoeia [7]. The USP and IP have recommended HPLC method for its assay 
while in BP method, it was estimated titrimetrically. 
It has been determined by a variety of analytical techniques such as HPLC [8-1.4], 
gas chromatography [15,16], capillary electrophoresis [17], HPTLC [18], polarimetry [19] 
and titrimetry [20]. Spectrbphotometric methods provide practical and significant economic 
advantages over other methods. The drug content in pharmaceutical preparations has been 
determined by two spectrophotometric methods [21] which are based on the formation of 
coloured complex of the drug with cobalt thiocyanate and methyl orange. The coloured 
species are extracted into organic solvents and measured at 630 nm and 420 nm with cobalt 
thiocyanate and methyl orange, respectively. Both the methods showed linearity in the 
range of 60-600 and 5-60 |ig ml'', respectively. Sastry et al. [22] have described two 
spectrophotometric methods for its determination based on the oxidation of diltiazem 
hydrochloride by Fe(III) or N-bromosuccinimide and estimating the reduced Fe(II) with 
1,10-phenanthroline or unreacted N-bromosuccinimide with metol-sulphanilamide, 
respectively. The acetate moiety in the drug is converted into hydroxamic acid which reacts 
with Fe (III) to form ferric hydroxamate that can be measured spectrophotometrically 
[23,24]. It was also determined in pharmaceutical preparations on the basis of reaction of 
hydrolyzed diltiazem hydrochloride with Folin-Ciocalteau reagent [25], The other 
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extractive spectrophotometric methods [26,27] have also been utilized for determination of 
diltiazem hydrochloride based on the formation of coloured ion pair complexes of the drug 
with reagents such as orange II, alizarin red-S, methyl orange, eriochrome black T, 
tropaeolin 0 0 and picric acid. The coloured ion-pair complexes were quantitatively 
extracted into chloroform and measured spectrophotometrically at 490, 440, 420, 510, 410 
and 404 run, respectively. However, many of these assay methods are limited in their 
applications or are rather tedious and time consuming. There is, therefore, a need for the 
development of simple spectrophotometric methods for the assay of diltiazem 
hydrochloride in pharmaceutical preparations. 
This chapter is divided into two sections, namely: 
[A] Extractive spectrophotometric methods for determination of diltiazem 
hydrochloride in pharmaceutical formulations using bromothymol blue, 
bromophenol blue and bromocresol green. 
[B] Spectrophotometric determination of diltiazem hydrochloride with sodium 
metavanadate. 
In section A, the spectrophotometric methods are discussed based on ion-pair 
complexes of the drug with dyestuffs such as bromothymol blue (BTB), bromophenol blue 
(BPB) and bromocresol green (BCG) and subsequent extraction into chloroform under 
reaction conditions used. 
The section B describes the spectrophotometric determination of diltiazem 
hydrochloride with sodium metavanadate in sulphuric acid medium. 
EXTRACTIVE SPECTROPHOTOMETRIC METHODS 
FOR DETERMINATION OFDILTIAZEMHYDRO-
CHLORIDE IN DRUG FORMULATIONS USING 
BROMOTHYMOL BLUE, BROMOPHENOL 
BLUE AND BROMOCRESOL GREEN 
f'jt^^ *». ,* * * > . * - J 
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EXPERIMENTAL 
Apparatus 
Spectronic 20D spectrophotometer (Milton Roy, USA) and an Elico model Li-10 pH 
meter were used for absorptiometric determination and pH measurement, respectively. 
Reagents and Buffer solutions 
The dyestuffs were used as 0.025% solutions of bromothymol blue (BTB), 
bromophenol blue (BPB) and bromocresol green (BCG), all in doubly distilled water. 
Sodium acetate-hydrochloric acid buffers [28] of pH 2.5, 2.8 and 3.5 were prepared by 
mixing 50 ml of 1.0 M sodium acetate solution with 50.50 ml or 49.50 ml or 46.25 ml of 
1.0 M HCl solution and diluted to 250 ml with doubly distilled water, respectively. The pH 
of each solution was adjusted to an appropriate value with the aid of a pH meter. 
Test Solution 
0.1 mg ml'' diltiazem hydrochloride (Sigma Chemical Co., USA) was prepared freshly 
in doubly distilled water. 
Analytical grade chloroform was used for extraction. 
Procedure for Calibration Curve 
Into a series of 50 ml separating funnels place 5 ml of buffer solutions of pH 2.8 (pH 
2.5 or pH 3.5) and 5 ml of BTB (BPB or BCG). To each funnel add an appropriate 
volume of 0.01% drug solution (0.25 - 2.00 ml for BTB; 0.25 - 1.00 ml for BPB; 0.25 -
1.25 ml for BCG) and mix well. Shake the funnels vigorously with 10 ml chloroform for 2 
minutes, then let them stand for clear separation of the two phases. Measure the absorbance 
of the organic phase at 415 nm, in each case, against a reagent blank similarly prepared. 
The calibration graphs are linear over the congsnlmtion ranges given in Table 3.1. The 
colour is stable for at least 3 hours. ^ V^.'^ ^^^ ' ^ \ 
; ( Ace. No -' 
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Procedure for the assay of dosage forms 
An amount of the tablet or capsule powder equivalent to 25 mg diltiazem 
hydrochloride was weighed accurately and extracted into 50 ml chloroform with shaking. 
Filtration through a Whatman No. 42 fiher paper was performed. The filtrate was 
evaporated to dryness under vacuum and the residue was taken up with doubly distilled 
water and transferred to a 250 ml standard volumetric flask, diluting to volume. The assay 
was completed using the procedure described in calibration curve. 
RESULTS AND DISCUSSION 
Diltiazem hydrochloride forms ion-pair complexes in acidic buffer with dyestuffs such 
as bromothymol blue (BTB), bromophenol blue (BPB) and bromocresol green (BCG) and 
these complexes are quantitatively extracted into chloroform. The absorption spectra of the 
ion-pair complexes extracted into chloroform are shown in Fig. 3.1. The ion-pair 
complexes with BTB, BPB and BCG absorbed maximally at 415 nm. The reagent blank 
under similar conditions showed no absorption. 
In order to establish molar ratio between diltiazem hydrochloride and dyestuffs used, 
the method of continuous variations [29] has been applied. In this method, solutions of 
drug and dyestuff with identical molar concentrations were mixed in varying volume ratios 
in such a way that the total volume of each mixture is the same. The absorbance of each 
solution was measured and plotted against the mole fraction of the drug, [drug]/[drug] + 
[dyestuff]; (Fig. 3.2). This measurement showed that 1:1 complex was formed with each 
dyestuff The formation constants [30,31] were also estimated and found to be 1.98 x 10^ 
1.46 x 10^  and 1.56 x 10^  for complexes with BTB, BPB and BCG, respectively. 
Diltiazem hydrochloride contains tertiary amino group which is protonated in acid 
medium, while sulphonic acid group is present in BTB that is the only group undergoing 
dissociation in the pH range 1-5 [32]. The BPB and BCG are the examples of 
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sulphonephthalein type of dyes [33]. The colour of such dyes is due to the opening of 
lactoid ring and subsequent formation of quinoid group. It is supposed that the two 
tautomers are present in equilibrium but due to strong acidic nature of the sulphonic acid 
group, the quinoid body must predominate. Finally the protonated diltiazem hydrochloride 
forms ion-pairs with the dyestuffs which are quantitatively extracted into chloroform. The 
possible reaction mechanisms are proposed and given in scheme 3.1. 
The influence of pH on the ion-pair formation of diltiazem hydrochloride with various 
dyestuffs has been studied using sodium acetate - hydrochloric acid buffer. The results are 
shown in Fig. 3.3. It is evident that absorbance of complexes with BTB, BPB and BCG was 
found to be constant v^thin the pH range 2.2-3.3, 2.0-3.0 and 2.8-3.8, respectively. Thus, 
all the absorbance measurements were made at pH 2.8, 2.5 and 3.5 with BTB, BPB and 
BCG, respectively. 
The effect of dyestuff concentrations was also studied by adding different volumes 
of dyestuff to a constant amount of diltiazem hydrochloride (60 \ig). It is apparent from 
Fig. 3.4 that the maximum absorbance, in each case, was found v/ith 2.0 ml of dyestuff, 
beyond which absorbance was constant. Thus, 5 ml of each dyestuff was used for ion-pair 
formation throughout the experiment. 
In the conditions mentioned above, the main figures of merit of the procedures 
proposed for determination of dihiazem hydrochloride have been established. Table 3.1 
summarizes the values for Beer's law limits, molar absorptivity, regression equation, 
correlation coefficients, relative standard deviation and recoveries. To test the 
reproducibility of the proposed methods, ten replicate determinations of 60 |ig of diltiazem 
hydrochloride were made. The coefficient of variation was found to be less than 1.2% for 
all the procedures. The results are summarized in Table 3.2. 
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[A] 
/OCH3 
Q ( _yO-OOCH3 ^ 
I 0 + ,CH3 
H 
diltiazem (protonated) bromothymol blue 
a:r°^ 
CH2-CH2-N<^ 
diltiazem-bromothymol blue complex 
ft"? C3H7 
[B] 
Br +H*' 
bromophenol blue (lactoid ring) (quinoid ring) 
O—COCHj + 
u + .CH, 
^ •^  ^ CH-, 
diltiazem (protonated) 
0 .CH3 
H - • 
diltiazem-bromophenol blue complex 
diltiazem (protonated) 
H -' 
diltiazem-bromocresol green complex 
Scheme 3.1. 
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4 5 
pH 
Fig. 5.3. Effect of pH :(a) 12 >ig ml drug + 5 ml of 
0.02555 BTB + 5 ml buffer of different pH values; (b) 6 j j g ml 
drug + 5 ml of 0.0255? BPB + 5 ml buffer of different pH values; 
(c) 6 pg ml" drug + 5 ml of 0.025« BCG + 5 ml buffer of 
different pH values. Each set is extracted into 10 ml Chloroform. 
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Volume of dye, ml 
Fig. 3.4. Influence of the volume of 0.025$g 
dye: (a) BTB; (b) BPB; (c) BCG. 
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The comparison of molar absorptivities and Beer's law limits of the proposed methods 
with those from other spectrophotometric methods is presented in Table 3.3. It can be seen 
from the table that those methods having broad dynamic linear range offered lower 
sensitivities, expressed as molar absorptivities. However, the methods proposed in this 
chapter present higher sensitivities with narrow analytical range but are comparable to 
other specfrophotometric methods [22]. The validity of the proposed methods has been 
tested by standard addition method. The results are summarized in Table 3.4. 
A systematic study of the effect of foreign species present along with diltiazem 
hydrochloride on the determination of diltiazem hydrochloride at 9.0 ^g ml"' level was 
undertaken. This study was carried out by following the proposed procedures for a 10 ml 
sample system, by adding a known amount of foreign species to a diltiazem hydrochloride 
solution of 9.0 fig ml"'. Table 3.5 summarizes the results obtained. However, the drug 
content from the powdered tablets or capsules was extracted into chloroform, which 
completely removes any interference by the common excipients found in formulations. 
The proposed methods have been successfully applied to the determination of diltiazem 
hydrochloride in pharmaceutical preparations. The performance order of the proposed 
methods is BPB>BCG>BTB. The results obtained shown in Table 3.6 were compared to 
those obtained by a reference method [23] by means of 't'-test at 95% confidence level. In 
all cases, the average results obtained by proposed methods and reference method were 
statistically identical, as the difference between the average values had no significance at 
95% confidence level. 
The proposed methods are simple, sensitive and reproducible and can be used for 
routine analysis of diltiazem hydrochloride in pure form and in formulations. 
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Table 3.5 
Effect of foreign species on the determination of 9.0 |ag ml"' 
diltiazem hydrochloride 
Foreign Species Maximum tolerance limit (mg)' 
Glucose 27.0 
Sucrose 51.3 
Fructose 27.0 
Lactose 54.1 
Starch 16.2 
* The same level was found for all the proposed procedures. 
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SPECTROPHOTOMETRIC DETERMINA TION OF 
DILTIAZEMHYDROCHLORIDE WITH SODIUM 
METAVANADATE 
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EXPERIMENTAL 
Apparatus 
All spectral and absorbance measurement were made on spectronic 20 D"" 
spectrophotometer (Milton Roy, USA) with 1 cm matched quartz cells. 
Reagents 
Sodium metavanadate, 1.0 M, prepared by dissolving 13.995 g of sodium metavanadate 
in boiling sulphuric acid and diluting to 100 ml with 11.0 M H2SO4. 
Test Solution 
1.2 mg ml'' diltiazem hydrochloride (Sigma Chemical Co., USA) was prepared freshly 
in doubly distilled water. 
Procedure for determination of diltiazem hydrochloride 
Into a series of boiling test tubes different volumes, corresponding up to 50 fig ml'', of 
drug solution were pipetted. To each test tube 2.6 ml of sodium metavanadate solution and 
4 ml of 13 M H2SO4 were added, mixed well and boiled gently for 20 min on a water bath. 
After heating for 20 min, the solutions were cooled at room temperature and transferred to 
a 10 ml volumetric flask and diluted to volume with doubly distilled water and the 
absorbance was measured at 750 nm against a reagent blank treated similarly. 
Procedure for the assay of capsules and tablets 
An accurately weighed quantity of the mixed contents of five capsules or five 
powdered tablets, equivalent to 60 mg of the drug, was extracted into 50 ml chloroform 
with shaking and the residue was filtered using Whatman No. 42 filter paper. The filtrate 
was evaporated to dryness and the residue was taken up with doubly distilled water and 
transferred to a 50 ml volumetric flask, diluting to volume. The assay was completed 
followdng the recommended procedure. 
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Procedure for reference method [22] 
Aliquots of 0.1-1.0 ml of 0.1% diltiazem hydrochloride were pipetted into a series of 
10 ml boiling test tubes. 1.5 ml of 0.003 M ferric chloride and 2.5 ml of 0.01 M 1,10-
phenan-throline were added successively in each test tube. The contents of each test tube 
were mixed well and heated on a boiling water bath for 30 min. After cooling the test tubes 
at room temperature, the solutions were transferred to 10 ml volumetric flasks, 2 ml of 
0.02M orthophosphoric acid was added in each flask and diluted to the mark with doubly 
distilled water. The absorbance was measured against a reagent blank at 495 nm. The 
amount of the drug in a given sample was computed from its calibration curve. 
RESULTS AND DISCUSSION 
The proposed method has been used for the determination of diltiazem hydrochloride 
by oxidation with sodium metavanadate in sulphuric acid mediimi. The blue colour formed 
is due to the reduction of vanadium (V) to vanadium(rV) by diltiazem hydrochloride in 
sulphuric acid medium. 
The optimum conditons for the formation of blue colour were studied and maintained 
throughout the studies. An investigation of the effect of reaction time (Fig. 3.5) showed 
that maximum colour was obtained when the reaction mixture is boiled gently for 20-25 
min on a water bath. The colour developed is measured at room temperature after dilution 
and mixing. The colour is stable for 5 hours. 
The effect of reagent concentration was studied by adding different volumes of sodium 
metavanadate solution to a constant amount of 500 ng per 10 ml of diltiazem 
hydrochloride. It was found that a maximum absorbance of the blue colour was with 2.5 
ml of reagent, beyond which absorbance was constant. Therefore 2.6 ml of sodium 
metavanadate was used throughout the experimental observation. 
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The second variable in colour development was the concentration of sulphuric acid. An 
investigation of the acidity showed that 7.9 - 8.5 M H2SO4 was sufficient to develop the 
colour. 
The absorption spectrum under the optimized conditions showed a maximum at 750 nm 
with a molar absorptivity, 6.18x10'' 1 mol"' cm"'. The absorbance measurements of the 
standard drug solution were made at 750 nm and a calibration curve was constructed by 
plotting absorbance versus concentration of the drug in ^g ml'' (Fig. 3.6). Beer's law is 
obeyed upto 50 |ig ml"' . The linear regression equation obtained was A=0.00+0.0137C 
(where C= concentration of diltiazem hydrochloride in |ig ml''), the correlation coefficient 
being r = 0.999, indicating an excellent linearity. 
The detection limit for the proposed method was found to be 0.02 |ag ml'' which was 
calculated by using the following relationship [34]: 
n 9 t 
Detection limit = v / S ^  — r T. V 0 n-1 b 
Where n= number of samples; b= slope of line of regression; t= student's t-value at 95% 
confidence level; So^  = variance = Z (A - Acaic.)^ / n - 2 [35]; (A = experimental value of 
absorbance; Acaic. = absorbance value calculated form the regression equation). 
The small value of variance, 3.84 x 10"^ , confirms the small degree of scatter of 
experimental data points around the line of regression. Both the detection limit and the 
slope of the calibration graph indicate the good sensitivity. 
The reproducibility of the method was calculated in terms of percent relative standard 
deviation (% R.S.D.) from the absorbance level of 10 different solutions at concentration 
level of 30.0 |j,g ml'' and the value was found to be 1.07% . The results are summarized in 
Table 3.7. 
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Fig. 3.6. Calibration curve for determination of 
diltiazem hydrochloride. 
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Table 3.7 
Test of precision of the proposed method 
Sample No. Absorbance Amovmt found 
C^igmr') 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
0.405 
0.410 
0.411 
0.412 
0.415 
0.417 
0.408 
0.413 
0.420 
0.409 
295.6 
299.2 
300.0 
300.7 
302.9 
304.3 
297.8 
301.4 
306.5 
298.5 
Relative Standard deviation = 1.07% 
Mean percent recovery = 100.23% 
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The drug content from the powdered tablets or capsules were extracted with chloroform 
which completely eliminates any interference by the common excipients found in 
formulations. 
The validity of the proposed method was performed by using standard addition 
technique. The results are summarized in Table 3.8. 
The applicability of the proposed method was assayed by analyzing commercial tablets 
and capsules. The assays were carried out as described under the experimental procedure 
for dosage forms. In all the preparations, the amount of diltiazem hydrochloride was 
obtained by direct measurement using the standard calibration curve. For the sake of 
comparison, diltiazem hydrochloride content of the pharmaceutical preparations was also 
determined by a reference method [22]. In every pharmaceutical preparations, the results 
were found to be very good (Table 3.9), thus confirming the validity of the proposed 
method. 
A statistical comparison between results obtained from both the proposed and reference 
methods was carried out. The calculated t-values did not exceed the theoretical values at 
95% confidence level, indicating the absence of any difference between the two methods. 
The procedure described here provides a rapid method for determination of diltiazem 
hydrochloride in bulk and dosage forms because of its simplicity, accuracy and 
reproducibility. The proposed method is comparable to other spectrophotometric methods 
[22,23] with respect to analysis time and does not require the prior extraction needed in 
some other methods [26,27,36]. It also provides practical and significant economic 
advantages over other instrumental methods. The method is thus suitable for routine 
analysis of diltiazem hydrochloride tablets and capsules. 
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Table 3.9 
Determination of diltiazem hydrochloride in dosage forms by the proposed method 
and reference method 
Nominal Proposed method Reference method [22] 
Preparations Composition Recovery RSD ? Recovery RSD t 
(mg) (%) (%)' (%) (%)" 
99.76 0.756 0.692 99.68 0.980 0.763 
99.45 0.630 2.023 99.58 0.809 1.200 
100.16 0.582 0.638 100.16 0.974 0.382 
99.74 0.385 1.555 100.06 0.805 0.185 
99.98 0.383 0.194 100.06 0.805 0.185 
99.55 0.677 1.549 99.88 1.050 0.283 
99.88 0.384 0.194 100.08 0.805 0.185 
*Five independent analyses. 
Vvalue at 95% confidence level is 2.776 
Dilcardia-30 
Angizem-30 
Diltime-30 
Dilzem-30 
Di4contin-60 
Kaizem CD 90 
Dilter CD 90 
30 
30 
30 
30 
60 
90 
90 
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CHAPTER 4 
ANALYSIS OFAMLODIPINEBESYLATE 
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INTRODUCTION 
Amlodipine besylate is an important calcium channel blocker belonging to the 
dihydropyridine family. It is more selective for arterial vascular smooth muscle than for 
cardiac tissue and is approved for the treatment of hypertension and for variant and stable 
angina. It is chemically known as 3-ethyl 5-methyl 2-(2-aminoethoxymethyl)-4-(2-
chlorophenyl)-l,4-dihydro-6-methyl pyridine-3,5-dicarboxylate monobenzene sulphonate. 
It is relatively a new calcium channel blocking agent with vasodilator activity similar to 
that of nifedipine[l]. 
The assay of the drug and its formulations are still not official in any pharmacopoeia. 
Therefore, the assay of the drug has been, and is still the subject of much investigation. The 
different analytical methods that are reported for its determination include high 
performance liquid chromatography [2-9], liquid chromatography coupled with tandem 
mass spectrometry [10], gas liquid chromatography [11], gas chromatography coupled with 
mass spectrometry [12], high performance thin layer liquid chromatography [13-15], and 
fluorometry [16]. The visible spectrophotometric methods are the instrumental methods of 
choice commonly used in industrial laboratories because of their simplicity, selectivity and 
sensitivity. In the literature only few spectrophotometric methods have been reported. 
Derivative spectrophotometric procedures have been described for simultaneous 
determination of amlodipine besylate with enalipril maleate or lisinopril or atenolol in 
combined tablet preparations [17,18]. The drug content in pharmaceutical preparations has 
been determined by spectrophotometric method [19], which involved the formation of an 
oxidative coupling product of drug with 3-methyl-2-benzothiazolinone hydrazone 
hydrochloride in the presence of eerie ammonium sulphate. Spectrophotometric method 
[20] based on the reaction with sodium hydroxide is reported for its determination in 
dosage forms. The yellow chromogen absorbed maximally at 456 nm and obeyed Beer's 
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law in the concentration range of 20-100 jig ml"'. Cetin et al. [21] have developed a 
sensitive analytical method for spectrophotometric assay of amlodipine besylate based on 
the formation of a coloured derivative during the reaction of drug with sodium 1,2-
naphthoquinone-4-sulphonate. The reaction proceeded quantitatively at pH 10 in 20 min. 
After the extraction of the derivative with 1-butanol, the absorbance was measured at 494 
nm. Extractive spectrophotometric methods [22,23] for determination of amlodipine 
besylate in tablet formulations have also been developed based on the formation of 
coloured chloroform extractable ion-pair complexes of the drug with bromocresol green, 
bromophenol blue, methylene blue, eriochrome black T and indigocarmine in acidic 
medium, which showed absorbance maxima at 409 nm, 409 nm, 668.2nm, 495 nm and 590 
nm, respectively. Singhvi and Chaturvedi [24] have described a spectrophotometric method 
in the visible region for estimation of amlodipine besylate in tablet formulations. The 
developed method is based on the formation of coloured chloroform extractable complex of 
drug with rhodizonic acid. However, some of the methods are somewhat tedious and time 
consuming. Therefore, the need for a fast, low cost and selective method is obvious, 
especially for routine quality control analysis of pharmaceutical products containing 
amlodipine besylate. 
This chapter describes the spectorphotometric determination of amlodipine besylate in 
pure form and drug formulations. The details of the methods are presented into two 
sections. 
[A] Spectrophotometric determination of amlodipine besylate by charge-transfer 
complex formation with p-chloranilic acid. 
[B] Spectrophotometric method for determination of amlodipine besylate with 
ninhydrin in drug formulations. 
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The first part of this chapter describes a rapid and simple visible spectrophotometric 
method for determination of amlodipine besylate exploiting its basic nature and electron 
donating property. The determination is based on the charge-transfer reaction with p-
chloranilic acid in 1,4-dioxan-chloroform medium. 
The second part describes another rapid, simple and sensitive visible 
spectrophotometric method based on the reaction of the primary amino group of 
amlodipine besylate wdth ninhydrin in N,N -dimethylformamide (DMF) medium. 
SPECTROPHOTOMETRIC DETERMINA TION OF 
AMLODIPINE BESYLATE BY CHARGE-TRANSFER 
COMPLEX FORMATION WITH 
p-CHLORANILIC ACID 
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EXPERIMENTAL 
Apparatus 
Absorbances were measured on spectronic 20 D"^  spectrophotometer (Milton Roy, 
USA) with 1 cm matched quartz cells. 
Reagents and Standard solutions 
A 0.5% amlodipine besylate (Wockhardt Ltd., India) in chloroform, 0.2% p-
chloranilic acid in 1,4-dioxan and 0.6 M aqueous sodium carbonate solutions were 
prepared. The p-chloranilic acid solution was stable at room temperature (-25 °C) for about 
two weeks. 
Preparation of amlodipine base solution 
Amlodipine base solution was prepared by transferring 25 ml of 0.5% amlodipine 
besylate solution into a 125 ml separating funnel followed by 50 ml of 0.6 M aqueous 
sodium carbonate solution. The contents of the separating funnel were mixed well and 
shaken for 1 min. The two phases were allowed to separate and the chlorform layer was 
dried over anhydrous sodium sulphate. 
Procedure for determination of amlodipine besylate 
Aliquots of 0.10 - 0.60 ml of amlodipine base solution were pipetted into a series of 5 
ml standard volumetric flasks. 2.0 ml of p-chloranilic acid was added to each and then 
diluted to volume with chloroform. The absorbance was measured within the stability 
period of 2 hours after dilution at 540 nm against a reagent blank prepared similarly 
omitting the drug. 
Procedure for determination of dosage forms 
An accurately weighed portion of the powdered tablet equivalent to 250 mg of 
amlodipine besylate was stirred well with 20 ml of chloroform and let stand for 10 min. 
The residue was filtered on a Whatman No. 42 paper and washed with chlorform. The 
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filtrate and washings were diluted to volume in a 50 ml volumetric flask. Amlodipine 
besylate solution was converted into amlodipine base following the procedure given under 
the head "preparation of amlodipine base solution" and then subjected to the recommended 
procediu'e for determination. 
RESULTS AND DISCUSSION 
The spectrum of p-chloranilic acid solution in dioxan-chloroform mixture exhibits 
absorption band at 440 nm. The addition of amlodipine base to this solution causes an 
immediate change in the absorption spectrum with a new characteristic band at 540 nm 
(Fig. 4.1). The band may be attributed to the formation of chloranilic acid radical anion. It 
has been reported that p-chloranilic acid exists in three forms [25], the neutral yellow H2A 
at very low pH, the dark violet HA" is most stable at pH 2 and the pale violet A?~ stable at 
high pH. The p-chloranilic acid in dioxan-chloroform exists in unionized form and acts as 
an n-acceptor in a similar maimer to quinones [26]. Some hydrochloride saUs of amines do 
not react with CT or u acceptors as they do not possess lone pair of electrons. Similarly, 
amlodipine besylate owing to the same reason is unable to react with p-chloranilic acid. To 
determine amlodipine besylate, it was dissolved in chloroform and shaken with 0.6 M 
aqueous sodium carbonate solution resulting in the formation of amlodipine base in 
chloroform layer. Therefore, the addition of p-chloranilic acid to amlodipine base 
possessing lone pair of electrons results in the formation of charge-transfer complex of n-n 
type. This compound is supposed to be an intermediate molecular association complex, 
which produces the corresponding radical ions in dioxan-chlorform solvent, which exhibits 
absorption band at 540 nm. The stoichiometric ratio of amlodipine base to p-chloranilic 
acid was determined by Job's method [27] and found to be 1:2 (Fig. 4.2). This confirms the 
presence of two n-donating centres in amlodipine base. A scheme for the chromogen 
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Fig. 4.1. Absorption spectra of (a) 2.30 x lO""" M 
chloranilic acid in 1,4—dioxan-chlorofornn; (b) 0.40 
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formation due to the reaction of amlodipine base and p-chloranilic acid can be assigned on 
the basis of literature baclcground and our findings. This may be outlined in scheme 4.1. 
The effect of volume of p-choranilic acid was studied by taking 0.3 ml of 0.5% 
amlodipine to which different volumes of 0.2% p-choranilic acid in 1,4 dioxan were added 
and the colour was formed instantly. The reaction mixture was diluted to 5 ml with 
chloroform and then the absorbances were recorded. The results show (Fig. 4.3) that the 
highest absorbance was obtained with 1.0 ml, which remained unaffected with higher 
amounts of p-choranilic acid. Hence, 2.0 ml of the reagent was used for determination. 
The effect of excipients frequently found in formulations such as talc powder, starch, 
lactose, glucose and magnesium stearate was evaluated using the proposed method. It was 
found that the common excipients did not interfere in the determination. 
Analytical data 
Under the optimum experimental conditions, the absorbance responses were linear in 
relation to the concentration of amlodipine besylate over the range 100 - 600 \xg ml"' 
(Fig. 4.4). The corresponding linear regression equation and coefficient of correlation, r are 
A = 0.004 + 0.00159 C and r = 0.9999 where C is the concentration of amlodipine besylate 
in [ig ml"'. The detection limit [28,29], molar absorptivity, standard deviation of the slope 
and variance were found to be 2.46 |ag ml"', 0.907 x 10^  1 mol"' cm"', 1.89 x 10"^ 1.66 x 
10"^ respectively. 
The variance is defined by the relationship [30]: S^ o = I](A-Acaicy/n-2; where A= 
experimental value of absorbance and Acaic. ~ value calculated from the regression 
equation. The small value of variance confirmed the small degree of scattering of 
experimental data points around the regression line. 
To check the reproducibility of the proposed method, ten replicate analyses of standard 
solutions each containing 2.0 mg of amlodipine besylate were carried out which gave an 
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91 
I I 1 I I I I I 
100 
I I I I I I I I I I I I 
400 500 600 
Cone, of drug, ;Lig ml"^ 
"1—I I I I—r 
200 300 
Fig.4.4. Calibration curve for determination of 
anniodipine besyiate. 
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average recovery of 100.11% with a relative standard deviation of 0.52%. The results are 
summarized in Table 4.1. 
As an additional demonstration of accuracy, recovery experiments were performed by 
applying the standard addition technique. In this study, 1.0 mg of amlodipine was added to 
each sample. Recoveries varying from 99.99 to 100.06% of amlodipine besylate from six 
marketed samples were obtained. This is good evidence of accuracy of the developed 
method. The results are listed in Table 4.2. 
The applicability of the proposed method for determination of amlodipine besylate in 
dosage forms was examined by analyzing marketed products and the results are 
summarized in Table 4.3. The results of the proposed method were statistically compared 
with those obtained by reference method [20]. It is evident from Table 4.3 that the 
calculated t-values are less than the theoretical ones at 95% confidence level, which 
indicates that there is no significant difference between the methods compared. 
The newly proposed method for determination of amlodipine besylate in 
pharmaceutical preparations was compared favourably with other spectrophotometric 
methods (Table 4.4). It was found that the method has the advantage of high precision 
(R.S.D. = 0.52% and 0.02 - 0.64% for pure and dosage forms, respectively) and fast 
response. It is concluded that the proposed method is simple, rapid, precise, and 
economical and therefore, can be successfully applied as an alternative to the existing 
methods. 
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Table 4.1 
Test of precision of the proposed method 
Sample 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
No. Absorbance 
0.641 
0.642 
0.636 
0.643 
0.639 
0.638 
0.646 
0.640 
0.645 
0.637 
Relative Standard deviation = 0.52% 
Mean percent recovery = 100.11% 
Amount found 
(Mg ml-') 
400.62 
401.25 
397.50 
401.87 
399.37 
398.75 
403.75 
400.00 
403.12 
398.12 
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Table 4.2 
Spectrophotometric determination of amlodipine besylate in pharmaceutical 
formulations by standard addition method 
Preparations^ 
Myodura-10 
Amlogard-10 
Amlong-10 
Amlosun-10 
Amloz-10 
Amtas-10 
Amount taken 
(^g ml-') 
100.00 
200.00 
100.00 
200.00 
100.00 
200.00 
100.00 
200.00 
100.00 
200.00 
100.00 
200.00 
Amount 
added 
(^g ml-') 
200.00 
200.00 
200.00 
200.00 
200.00 
200.00 
200.00 
200.00 
200.00 
200.00 
200.00 
200.00 
Total amount 
found 
(^g ml-')" 
299.99 
399.99 
300.20 
400.20 
299.99 
399.99 
300.20 
400.20 
300.20 
399.99 
300.20 
400.00 
Recovery 
(%) 
99.99 
99.99 
100.06 
100.05 
99.99 
99.99 
100.06 
100.05 
100.06 
99.99 
100.06 
100.00 
RSD 
(%)" 
0.21 
0.16 
0.32 
0.24 
0.21 
0.16 
0.32 
0.24 
0.32 
0.16 
0.43 
0.31 
*Drug samples are in tablet form. 
''Three independent analyses. 
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Table 4.3 
Spectrophotometric determination of amiodipine besylate in pharmaceutical 
formulations by the proposed method and reference method 
Pharmaceutical 
formulations 
Myodura 
Amlogard 
Amlong 
Amlosun 
Amloz 
Amtas 
Labelled 
amount 
(mg) 
10 
10 
10 
10 
10 
10 
Proposed 
Recovery 
(%) 
99.99 
100.03 
99.99 
100.09 
100.09 
100.09 
method 
RSD 
0.25 
0.30 
0.25 
0.32 
0.32 
0.38 
t^  
0.02 
0.22 
0.02 
0.64 
0.64 
0.55 
Reference method [20] 
Recovery RSD t" 
(%) {%f 
100.02 
99.97 
100.02 
100.02 
100.05 
100.15 
0.27 
0.18 
0.27 
0.35 
0.24 
0.41 
0.20 
0.30 
0.20 
0.16 
0.46 
0.82 
^Five independent analyses. 
''t-value at 95% confidence level is 2.776. 
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Table 4.4 
Comparison of the proposed method with existing spectrophotometric methods for 
determination of amlodipine besylate in pharmaceutical formulations 
Reagent 
Bromocresol green^ 
Bromophenol blue* 
Methylene blue* 
Sodium hydroxide 
Bromothymol blue* 
MBTH'' 
Eriochrome black T* 
Indigocarmine* 
Rhodizonic acid* 
p-Chloranilic acid 
^max 
(nm) 
409.0 
409.0 
668.2 
456.0 
405.0 
630.0 
495.0 
590.0 
450.0 
540.0 
Beer's law limit 
(^gml-') 
0 -80 
0-80 
0-80 
20 - 100 
5-40 
5-40 
5-50 
25-150 
100-1,500 
100-600 
Molar absorptivity 
(1 mor'cm-') 
-
-
-
-
1.98x10'' 
9.07x10^ 
6.54x10^ 
1.96x10^ 
-
0.907x10^ 
RSD 
(%) 
-
-
-
1.90 
0.99 
0.87 
0.88 
0.87 
-
0.52 
References 
22 
22 
22 
20 
19 
19 
23 
23 
24 
This work 
*Extractive method. 
3-methyl-2-benzothiazolinone hydrazone hydrochloride. 
SPECTROPHOTOMETRIC METHOD FOR 
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EXPERIMENTAL 
Apparatus 
A Milton Roy Spectronic 200"" spectrophotometer (Milton Roy Co., USA) was used for 
all absorbance measurements. A water bath shaker (NSW 133, India) was used to control 
the heating temperature for colour development. 
Reagents and Standards 
All the reagents used were of analytical grade. A 0.1% amlodipine besylate (Wockhardt 
Ltd., India) solution was prepared in N,N'-dimethylformamide (DMF). A 0.06 M ninhydrin 
(E. Merck) solution was also prepared in DMF. Freshly prepared ninhydrin solution was 
always used. 
Procedure for the assay of amlodipine besylate 
Aliquots of 0.10-0.60 ml amlodipine besylate standard solution were pipetted into a 
series of boiling test tubes. To each test tube 1.5 ml of ninhydrin solution was added, 
mixed well and heated on a water bath at 100±1°C for 5 min. After heating, the solutions 
were cooled at room temperature and transferred to a 10 ml volumetric flask and diluted to 
volume with DMF. The absorbance was measured at 595 run against a reagent blank 
treated similarly. 
Procedure for the assay of amlodipine besylate in pharmaceutical preparations 
Twenty tablets were accurately weighed and powdered. A portion equivalent to 50 mg 
amlodipine besylate was stirred with 20 ml of DMF, let stand for 10 min, the residue was 
filtered on a Whatman No. 42 filter paper and washed with DMF. The filtrate and washing 
were diluted to volume in a 50 ml volumetric flask and subjected to the procedure for 
determination. 
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RESULTS AND DISCUSSION 
The ninhydrin has been known as a reagent for the detection of amino acids and 
amines since 1910 and therefore, a number of theories have been put forward to explain the 
mechanism of its reaction. It was suggested that the reactions of ninhydrin with amine, 
amino acids and imino acids all proceed by the same mechanism [31]. The interpretation 
was based on the mechanism of Strecker degradatoin and explained the formation of 
diketohydrindylidene-diketohydrindamine or the Ruhemann's purple. The chemistry of the 
colour reaction may be suggested on the basis of the above theories. The primary amino 
group present in amlodipine besylate reacts with ninhydrin under the prescribed conditions 
giving the first intermediate (I). This reaction is the first step of the Strecker degradation. 
The zwitter ion (II) is then produced which involves the dehydration. The product (III) is 
obtained by hydrolysis of (II) which was highly reactive and it might condense further with 
ninhydrin to give diketohydrindylidene - diketohydrindamine (IV). This compound would 
further react with amino group to give the product which absorbed maximally at 595 nm. 
The reaction mechanism is shown in Scheme 4.2. 
The absorption spectrum of the coloured product is shown in Fig. 4.5. The maximum 
absorbance was obtained at 595 nm. The optimum conditions for determination of 
amlodipine besylate were established via a number of preliminary experiments. 
Effect of heating time 
A 0.5 ml of 0.1% amlodipine besylate was mixed with 1.5 ml of 0.06 M ninhydrin 
solution. The reaction mixture was heated on a water bath at 100±rC. A coloured product 
was obtained and the intensity of the colour was reached to maximum after four minutes of 
heating. The content of the boiling tube was transferred to 10 ml standard volumetric flask 
and diluted to volume with DMF. Hence, the absorbance was measured after 5 minutes of 
heating. The results are shown in Fig. 4.6. 
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Effect ofninhydrin concentration 
To 0.5 ml of 0.1% amlodipine besylate, different volumes of 0.06 M ninhydrin were 
added. The reaction mixtures were heated for 5 minutes on a water bath at 100±rC. The 
coloured product was diluted to 10 ml with DMF and the absorbance was measured against 
a reagent blank at 595 nm. The results showed that the highest absorbance was obtained 
with 1.3 ml which remained unaffected with higher amounts ofninhydrin (Fig. 4.7). A 1.5 
ml of the reagent, therefore, was added for determination. 
Analytical Data 
Beer's law limit, molar absorptivity, detection limit, regression equation and 
correlation coefficient were obtained by least square treatment of results. The linear 
relationship was found between absorbance at X,max and concentration of drug in the range 
10-60 \i.g ml'' (Fig. 4.8). Regression analysis of Beer's law plot at 595 nm yielded the 
regression equation, A = 0.001 + 1.149 x 10"^  C (where C= concentration in |ag ml"') and 
revealed a good correlation coefficient (r= 0.9999) indicating an excellent linearity. The 
molar absorptivity and the detection limit were found to be 6.52 x 10^  / mol"' cm'' and 0.22 
\ig ml'', respectively. The detection limit was calculated using the equation [28,32]: 
Detection limit = v / S ^  —V -r V 0 n-1 b 
Where n= number of samples; b= slope of line of regression; t= student's t-value at 95% 
confidence level and So^  = variance. The detection limit and the slope of the calibration 
graph indicated the good sensitivity of the method and the small value of variance, 9.96 x 
10"^  confirmed the small degree of scattering of experimental data points around the line of 
regression. 
The reproducibility of the proposed method was checked with ten replicate 
determinations of 0.4 mg of amlodipine besylate and the relative standard deviation was 
calculated. The results are summarized in Table 4.5. 
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Table 4.5 
Test of precision of the proposed method 
Sample No. Absorbance Amount found 
(^g ml-') 
1 0.460 40.00 
2 0.462 40.17 
3 0.463 40.26 
4 0.459 39.91 
5 0.458 39.82 
6 0.456 39.65 
7 0.457 39.73 
8 0.461 40.08 
9 0.456 39.65 
10 0.464 40.34 
Standard deviation = 0.26 
Relative Standard deviation = 0.66% 
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Beer's law limit and relative standard deviation of the proposed method are compared 
with that of other spectrophototometric procedures described in the literature [19,20,22]. It 
is worth noticing that Beer's law limit of the proposed method is quite reasonable with high 
precision. 
In order to investigate the applicability of this spectrophotometric method to the 
determination of amlodipine besylate alone or in pharmaceutical preparations, the effect of 
the presence of some common excipients such as starch, talc, lactose and magnesium 
stearate was studied. It was found that the common excipients did not interfere in the 
determination. 
The validity of the proposed method for determination of drug in pharmaceutical 
preparations was tested by applying the standard addition technique. The results obtained 
were reproducible with low relative standard deviations (0.21 - 0.45%) and the mean 
recoveries were in the range of 99.96 - 100.12%. The results are reported in Table 4.6. 
Commercial formulations containing amlodipine besylate were successfully assayed by 
the proposed method. The results were compared to those obtained by the reference method 
[20], which are listed in Table 4.7. The performance of the proposed method was judged by 
calculating t- and F-values. At 95%) confidence judged level, the calculated t- and F-values 
do not exceed the theoretical values indicating no significant difference between the 
proposed method and the reference method. 
It is concluded that the proposed method is rapid and simple for determination of 
amlodipine besylate in bulk and commercial formulations with good accuracy and 
precision. The short analysis time and low cost are the main advantages of the developed 
method for routine analysis. 
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Table 4.6 
Spectrophotometric determination of amiodipine besylate in pharmaceutical 
preparations by standard addition method 
Preparations^ 
Myodura-lO 
Amlong-10 
Amlogard-10 
Amlosun-10 
Amloz-10 
Amtas-10 
Amount 
taken 
(Mg ml-') 
10.00 
20.00 
10.00 
20.00 
10.00 
20.00 
10.00 
20.00 
10.00 
20.00 
10.00 
20.00 
Amount 
added 
(^ ig ml-') 
20.00 
20.00 
20.00 
20.00 
20.00 
20.00 
20.00 
20.00 
20.00 
20.00 
20.00 
20.00 
Total amount 
found 
(^g ml-')" 
29.99 
39.99 
30.02 
40.05 
30.02 
40.02 
30.02 
40.02 
30.02 
40.05 
29.99 
39.99 
Recovery 
(%) 
99.96 
99.97 
100.06 
100.12 
100.06 
100.05 
100.06 
100.05 
100.06 
100.12 
99.96 
99.97 
RSD 
(%)' 
0.28 
0.21 
0.44 
0.45 
0.44 
0.33 
0.44 
0.45 
0.44 
0.45 
0.28 
0.21 
^Drug samples are in tablet form. 
^Five independent analyses. 
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Table 4.7 
Spectrophotometric determination of amlodipine besylate in pharmaceutical 
preparations by the proposed method and reference method 
Pharmaceutical Labelled 
Preparations amount 
(mg) 
Myodura 
Amlong 
Amlogard 
Amlosun 
Amloz 
Amtas 
10 
10 
10 
10 
10 
10 
Proposed 
Recovery 
(%) 
100.02 
99.97 
100.10 
100.10 
100.15 
100.02 
method 
RSD t" 
(%)" 
0.42 
0.34 
0.50 
0.50 
0.42 
0.42 
0.13 
0.16 
0.44 
0.44 
0.79 
0.13 
Reference method [20] 
Recovery RSD t" 
(%) (%)" 
100.02 
100.02 
99.97 
100.02 
100.05 
100.15 
0.27 
0.27 
0.18 
0.35 
0.24 
0.40 
0.20 
0.20 
0.30 
0.16 
0.46 
0.82 
F<= 
2.33 
1.55 
2.08 
2.08 
2.94 
1.06 
^Five independent analyses, 
''t-value at 95% confidence 1 
•^ F-value at 95% confidence level is 6.39. 
lvalu  level is 2.776. 
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CHAPTER 5 
SPECTROPHOTOMETRIC METHOD FOR 
DETERMINATION OF VERAPAMIL 
HYDROCHLORIDE IN PHARMACEUTICAL 
FORMULATIONS USING N-BROMOSUCCINIMIDE 
AS OXIDANT 
I l l 
INTRODUCTION 
Verapamil hydrochloride is a potent antihypertensive agent and belongs to the class of 
calcium channel blockers. It has been approved for the intravenous therapy of 
supraventricular tachyarrhythmias because of its significant depressant effects [1]. The 
drug is chemically known as 5-[N-(3,4-dimethoxyphenyl ethyl) methylamino]-2-(3,4-
dimethoxyphenyl)-2-isopropyl valeronitrile hydrochloride. The drug is officially listed in 
British Pharmacopeia [2], The United States Pharmacopoeia [3] and The Indian 
Pharmacopoeia [4] which describes a non-aqueous titration for its assay in bulk and 
dosage forms. 
Several methods have been employed to determine verapamil hydrochloride in 
biological specimens and /or pharmaceutical formulations. The determination in biological 
fluids normally requires the use of trace analysis techniques, mainly chromatography with 
fluorimetric [5-7] or UV [8-10] detection. Verapamil hydrochloride is present in relatively 
large amovmts in pharmaceutical formulations. Therefore, much effort has been made to 
develop simple, rapid, accurate and precise analytical procedures. Of these cited in 
literature, some spectrophotometric methods have been utilized for assay of drug in 
commercial dosage forms. Other methods include high performance liquid chromatography 
[11-16], high performance thin layer chromatography [17], gas liquid chromatogrphy [18], 
capillary gas chromatography [19], potentiometry [20] and potentiometry - conductometry 
[21]. 
Verapamil hydrochloride has been determined in the visible region based on the 
charge-transfer complexes with chloranil [22], chromo trope 2B and chromotrope 2R azo 
dye [23], p-chioranilic acid and 2,3 -dichloro 5,6-dicyano p-benzoquinone [24]. Extractive 
spectrophotometric methods have been reported for the assay of drug in commercial 
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dosage forms which are based on the coloured complexes of the drug with the reagents like 
bromophenol blue, bromocresol purple, bromocresol green, methyl orange and 
bromothymol blue [25]; solochrome black T, solochrome dark blue, fast sulfone FF and 
solochrome cyanin R [26]; erioglaucine and indigocarmine [27] and alizarin red-S [28] in 
acid medium. However, simple spectrophotometric procedure based on the reaction of drug 
with oxidant is not known. 
This chapter describes a fast, simple and accurate spectrophotometric method for the 
determination of verapamil hydrochloride based on its reaction with N-bromosuccinimide. 
The reaction conditions were thoroughly studied and under optimum experimental 
conditions, the procedure provides a highly sensitive method for determination of the drug 
in commercial dosage forms. 
EXPERIMENTAL 
Apparatus 
A Spectronic 20 D"^  spectrophotometer (Milton Roy, USA) was used to measure the 
absorbance. 
Reagents and Standards 
A 0.1% verapamil hydrochloride solution (Sigma Chemical Co., USA) and 0.25% N-
bromosuccinimide solution were freshly prepared in doubly distilled water. The drug 
samples were purchased locally. 
Procedure for determination of verapamil hydrochloride 
Aliquots of 0.10-2.0 ml of verapamil hydrochloride solution were pipetted into a series 
of 10 ml standard volumetric flasks. A 2.5 ml of 0.25% N-bromosuccinimide and 3.0 ml 
of 5 M HCIO4 were added to each flask and then diluted to volume with doubly distilled 
water at 25±rC. The contents were mixed thoroughly and waited for 3 min to complete 
the reaction and then the absorbance was measured at 415 nm against a reagent blank in 
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the stability period (3-45 min). The calibration curve obtained by plotting the absorbance 
against the concentration of verapamil hydrochloride was utilized to determine the amount 
of verapamil hydrochloride in a given sample. 
Procedure for determination of verapamil hydrochloride in pharmaceutical 
formulations 
Twenty tablets were accurately weighed and powdered. A portion equivalent to 100 mg 
verapamil hydrochloride was extracted into 100 ml chloroform. The chloroform layer was 
evaporated to dryness. The left drug was taken up with doubly distilled water and 
transferred to a 100 ml standard flask, diluting to volume. The assay was completed 
following the recommended procedure. 
RESULTS AND DISCUSSION 
N-bromosuccinimide acts as an oxidizing agent which converts primary and secondary 
aromatic alcohols into the corresponding aldehydes and ketones, respectively [29]. The 
oxidizing action of N-bromosuccinimide has been widely used to bring about the 
stereoselective oxidation of steroid alcohols [30,31]. N-bromosuccinimide also reacts with 
tertiary amines where carbon-nitrogen bond scission occurs readily with the formation of 
aldehyde and secondary amine [32]. The results of such studies suggest that a methyl or 
methylene group attached to nitrogen is required and N-CH2 linkage is cleaved 
preferentially and the resulting compounds give yellow colour. Verapamil hydrochloride 
was found to yield a clear yellow product with N-bromosuccinimide in perchloric acid 
medium having absorbance maximum at 415 run (Fig. 5.1). Verapamil hydrochloride was 
oxidized by N-bromosuccinimide in perchloric acid medium. It was supposed that on 
treatment with N-bromosuccinimide, N-CH2 bond was cleaved which resulted the 
formation of aldehyde and secondary amine while N-bromosuccinimide was irreversibly 
reduced to succinimide with the formation of hydrogen bromide. It has been confirmed that 
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bromine was not evolved during this reaction. Therefore, based on the literature 
background and our findings, the reaction mechanism was proposed and given in 
Scheme 5.1. 
Preliminary experiments were carried out to determine the optimum conditions for 
quantitative estimation of verapamil hydrochloride. 
Effect of the concentration of perchloric acid 
The influence of the volume of 5 M HCIO4 on the reaction has been studied and the 
results are shown in Fig. 5.2. The highest absorbance was obtained by using 2.0 ml of 5 M 
HCIO4, above this volume the absorbance remains constant. A volume of 3.0 ml, therefore, 
was used in all further measurements. 
Effect of the concentration ofN-bromosuccinimide 
To 1.2 ml of 0.1% verapamil hydrochloride, different volumes of 0.25 % N-
bromosuccinimide were added. The reaction mixtures were treated with 3.0 ml of 5 M 
HCIO4 and then diluted to 10 ml with doubly distilled water. The absorbances were 
recorded at 415 nm. The results showed (Fig. 5.3) that the highest absorbance was obtained 
with 1.3 ml, which remained unchanged with higher volumes of N-bromosucciniminde. 
Therefore, 2.5 ml of the reagent was used for determination. The intensity of the colour 
formed, reached maximum in three min after mixing the reagent at room temperature and 
was stable upto 45 min. Therefore, it is recommended that the absorbance be measured 
within this time period. 
Analytical data 
Under the optimum experimental conditions, there was a linear correlation between the 
absorbance at 415 nm and the final concentration of the drug over the range 10-200 
[xg ml'' (Fig. 5.4). The regression analysis using the method of least square was made 
which yielded the linear regression equation, A= 0.003 + 0.00519 C and coefficient of 
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correlation, r = 0.9999 where A is absorbance and C is the concentration of verapamil 
hydrochloride in |ig ml"'. The molar absorptivity, detection limit [33,34] and standard 
deviation of the slope of regression line were found to be 2.55 x 10 / mol' cm' , 1.40 (ig 
ml'' and 2.45 x 10'^  \xg ml'', respectively. 
The effect of the common excipients present in formulations was studied and the results 
are summarized in Table 5.1. The drug content from the powdered tablets was extracted 
with chloroform, which completely eliminates any interference by the common excipients 
found in formulations. 
Precision and accuracy 
In order to study the precision and accuracy of the proposed method, ten replicate 
analyses on samples, each containing 1.0 mg, were performed which gave a mean recovery 
of 100.13% with relative standard deviation of 0.57%. The mean recovery and RSD can be 
considered to be very satisfactory. The results are summarized in Table 5.2, 
As an additional demonstration of accuracy, recovery experiments were carried out by 
adding a fixed amount of the pure drug to the preanalyzed commercial dosage forms. The 
results obtained were reproducible with low RSD (0.15 - 0.44%) and mean recoveries were 
in the range of 99.99 -100.14% (Table 5.3). 
The proposed method is successfully applied to the determination of commercial 
dosage forms, viz. Calaptin-80, Isoptin-80 and Vasopten-80 tablets. The results of the 
proposed method were statistically compared with those obtained by The Indian 
Pharmacopoeia method [4]. Table 5.4 shows that the calculated t- and F- values are less 
than the theoretical ones at 95% confidence level indicating that there is no significant 
difference between the methods compared. 
The proposed procedure for assay of verapamil hydrochloride in pharmaceutical dosage 
forms was compared favourably with other spectrophotometric methods. As can be seen 
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Table 5.1 
Effect of foreign species on the determination of 100 ^g ml"' verapamil 
hydrochloride 
S.No. Foreign Species Maximvim tolerance limit (mg) 
1 
2 
3 
4 
5 
Glucose 
Sucrose 
Fructose 
Lactose 
Starch 
27.00 
68.46 
36.03 
68.46 
20.00 
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Table 5.2 
Test of precision of the proposed method 
Sample No. Absorbance Amount found 
(^g ml-') 
1 0.523 100.57 
2 0.516 99.23 
3 0.522 100.38 
4 0.520 100.00 
5 0.522 100.38 
6 0.525 100.96 
7 0.524 100.76 
8 0.518 99.61 
9 0.520 100.00 
10 0.517 99.42 
Relative standard deviation = 0.57% 
Mean percent Recovery = 100.13% 
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Table 5.3 
Spectrophotometric determination of verapamil hydrochloride in pharmaceutical 
formulations by standard addition method 
Pharmaceutical 
formulations^ 
CaIaptin-80 
Isoptin-80 
Vasopten-80 
Amount taken 
(^g ml-') 
20 
50 
50 
20 
50 
50 
20 
50 
50 
Amount 
added 
(^g ml-') 
30 
50 
100 
30 
50 
100 
30 
50 
100 
Total amount 
found 
(Mg ml-')" 
50.07 
100.07 
150.07 
50.03 
99.99 
150.07 
50.03 
100.07 
150.07 
Recovery 
(%) 
100.14 
100.07 
100.05 
100.07 
99.99 
100.05 
100.07 
100.07 
100.04 
RSD 
(%)" 
0.44 
0.22 
0.15 
0.29 
0.31 
0.15 
0.32 
0.22 
0.27 
^Drug formulations are in tablet form. 
"Five independent analyses. 
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Table 5.4 
Spectrophotometric determination of verapamil hydrochloride in pharmaceutical 
formulations by the proposed method and reference method 
Pharmaceutical Proposed method Reference method [4] F'^  
Formulations Recovery RSD ? Recovery RSD ? 
(%) (%)" (%) (%)" 
Calaptin-80 99.99 0.20 0.07 100.09 0.25 0.89 2.37 
Isoptin-80 100.05 0.15 0.15 100.07 0.28 0.73 1.46 
Vasopten-80 100.02 0.19 0.19 100.03 0.24 0.31 2.23 
*Five independent analyses. 
Vvalue at 95% confidence level is 2.776. 
"^ F-value at 95% confidence level is 6.39. 
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from Table 5.5 that the present method has the advantages of wider linear dynamic range 
with low RSD and fast response. 
Being of good accuracy and of high precision, simple and fast, the present 
spectrophotometric method could be recommended for routine analysis of verapamil 
hydrochoride in drug quality control laboratories. 
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Table 5.5 
Comparison of the proposed method with other spectrophotometric methods for 
determination of verapamil hydrochloride in pharmaceutical formulations 
Reagent 
Bromophenol blue" 
Bromothymol blue^ 
Bromocresol green* 
Methyl orange* 
Bromocresol purple* 
Solochrome black T* 
Solochrome dark blue* 
Fast Sulphone - FF* 
Solochrome cyanin R* 
Eriogloucine* 
Indigocarmine* 
Chromotrope 2 B 
Chromotrope 2 R 
Alizarin red - S* 
N-Bromosuccinimide 
^max 
(nm) 
420 
420 
420 
420 
420 
527 
528 
515 
445 
627 
602 
530 
546 
426 
415 
Beer's law limit 
C^igmr') 
4 -16 
4 -20 
4 -20 
4 -16 
4 - 2 4 
8-32 
10-38 
8-32 
8-30 
1.3-5.3 
33-130 
4.91-58.93 
4.91-58.93 
10-100 
10-200 
RSD 
(%) 
-
-
-
-
-
0.78 
1.53 
0.87 
1.24 
1.45 
1.53 
-
-
-
0.57 
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Nifedipine, i.e. dimethyl-l,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl) pyridtne-3,5-
-dicarboxylate is an important calcium channel blocker (1). The main effects of this drug 
are confined to cardiac and smooth muscles. Therefore, the analysis of its dosage forms 
is very important. 
Thin-layer chromatography was first used for qualitative analysis of nifedipine in 
commercial dosage forms and then quantitative estimation was done either by 
chromatographic-spectrometric method or by gas chromatrography coupled with mass 
spectrometry (2). High performance liquid chromatrographic methods (3, 4) were 
widely used for identification of nifedipine and its photodegradation products. Re-
versed phase HPLC methods have also been discussed for its determination in human 
plasma and serum (5, 6). Nifedipine was also determined by a number of gas chroma-
tographic methods (7-9). 
Nifedipine was estimated in capsules and tablets by UV-visible spectrometry at 340 
nm (10). It has been also determined in pharmaceuticals by spectrometry based on 
measuring yellow colour produced by reaction of methanolic solution of the drug with 
4-dimethylaminobenzaldehyde in H3PO4 at 380 nm (11). Sastry and coworkers (12) have 
developed a spectrometric method for its determination. The method involved the for-
mation of a blue complex on treatment with Folin-Ciocalteau reagent and was subse-
quently determined at 600 nm. Nifedipine and atenolol in combined preparations have 
been determined spectrometrically using the first derivative spectra of their solutions in 
methanol (13). The quantification of nifedipine alone was done using second-order de-
rivative spectra of the compound in 0.1 mol L"^  HCl (14). Simultaneous determination of 
nifedipine and acebutolol hydrochloride in pharmaceutical preparations has been per-
' Correspondence 
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formed by first derivative spectrometry at 400 and 352 nm, respectively (15). The Beer's 
law was obeyed in the range of 4-12 ng mL"^  for nifedipine. Another first derivative 
spectrometric method has also been described for simultaneous determination of nife-
dipine and mefruside (16). The first derivative method depends on the measurement of 
the derivative amplitude at 390 and 282 nm for determination of nifedipine and mefru-
side, respectively. 
Our communication describes kinetic spectrometric determination of nifedipine in 
pure form and in pharmaceutical preparations. 
EXPERIMENTAL 
A Bausch and Lomb Sppctronic 20D* spectrophotometer (Bausch and Lomb, USA) 
was used to record the absorbance. 
All chemicals used were of analytical or pharmaceutical grade. A 0.1% nifedipine 0-
B. Chemicals and Pharmaceuticals Ltd., India) solution was prepared in methanol and 
protected from light. A 0.1% potassium permanganate was freshly prepared in doubly 
distilled water. 
Nifedipine determination procedure 
Aliquots of 0.18-0.44 mL of nifedipine standard solution were pipetted into a series 
of 10-mL standard volumetric flasks. One mL of 0.1% potassium permanganate was 
added in each and then diluted to volume with doubly distilled water at 30 ± 1 °C. After 
.mixing, reaction mixture was immediately transferred to spectrometric cell and the ab-
sorbance recorded as a function of time at 530 nm. The initial rate of the reaction (v) at 
different concentrations was obtained from the slope of the tangent to the absorbance-
-time curve. The calibration curve was obtained by plotting logarithm of the intial rate 
of the reaction (log v^) vs. logarithm of the concentration of nifedipine (log c). 
Determination of nifedipine in pharmaceutical preparations 
Twenty tablets were weighed accurately, ground to a powder and mixed. An aliquot 
equivalent to 50 mg of nifedipine was stirred with 20 mL of methanol, let stand for 10 
min, the residue filtered on a Whatman No. 42 paper and washed with methanol. The 
filtrate and washing were diluted to volume in a 50-mLvolumetric flask and subjected 
to the procedure for determination. 
RESULTS AND DISCUSSION 
Potassium permanganate is an oxidising agent with an absorption maximum at 530 
nm. The oxidation of nifedipine by potassium permanganate at neutral pH was fol-
lowed spectrometrically by measuring the decrease in absorbance at 530 nm. Figs. 1 and 
2 show the absorbance-time curves of varying concentration of nifedipine at a fixed 
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KMnO^ concentration and of varying KMn04 concentration at a fixed nifedipine con-
centration, respectively. The slope of the tangent to the absorbance-time curve is used as 
a measure of the intial rate of the reaction. The rate at which permanganate is consumed 
Fig. 1. Absorbance-time curves: KMn04 
6.32 X 10^ mol L-' and nifedipine: 
a) 8.66 X 10-5 mol L"'; b) 1.16 x lO"^  mol L"'. Time (min) 
20.00 
V 
a 
a 0.40 
XI 
< 
"n I 1—]—I—I—I—r 
10.00 
Time (min) 
20.00 
Fig. 2. Absorbance-time curves: nifedip-
ine 2.89 X 10^ mol L-i and KMnO :^ 
a) 3.16 X 1(H mol L"'; b) 1.27 x 10-" mol L"'. 
obeys first-order rate when nifedipine is in excess. Hence, the order of the reaction with 
respect to permanganate is one. the order with respect to nifedipine is found to be two, 
the overall order being three. The following kinetic equation is proposed for nifedipine-
potassium permanganate reaction: 
- d[KMnO.] 
d( : fc[nifedipine]2 [KMn04] 
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The oxidation of nifedipine has been studied earlier (17) and therefore, its oxidation 
by dilute aqueous KMn04 at pH 7.2 ± 0.2 may proceed as shown in the following equa-
tion: 
OH 
I H,COOC-r >—COOCHj + MnO^ 
i i J-CH, COOCHJ + HO—Mn—O" 
The disproportionation between immediate oxidation states of manganese results 
finally in the formation of MnOj. However, no precipitation of Mn02 has been observed 
under study time period. 
Calibration curve showed a linear relationship over nifedipine concentration range 
of 18-44 )ig mL-i. The linear regression analysis shows that log VQ = 6.086 + 1.960 log c 
with correlation coefficient r = 0.998 
The precision of the proposed kinetic method was checked by ten replicate determi-
nations of 0.25 mg nifedipine. Relative standard deviation and mean percent recovery 
were 1.5% and 100.2%, respectively. Results are summarised in Table I. The validity of 
the proposed kinetic method was checked by applying standard addition method and 
the results are reported in Table II. 
A study of interference of some compounds has been made during determination of 
0.25 mg nifedipine. It has been found that starch and sucrose could be tolerated with a 
maximum amount of 68.5 mg and 16.2 mg, respectively. 
The proposed method has been applied to the nifedipine determination in pharma-
ceutical preparations. The results obtained by this method were in good agreement with 
those obtained by the BP method (18). 
Table I. Precision testing of the proposed kinetic method 
Sample No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Initial reaction rate 
(mol L-' min-i) 
9.60 X 10-3 
9.20 X 10-3 
9.13 X 10-3 
9.38 X 10-3 
9.33 X 10-3 
9.75 X 10-3 
9.91 X 10-3 
9.00 X 10-3 
9.14 X 10-3 
9.56x10-3 
Amount of nifedipine found 
(ng per 10 mL) 
254.8 
248.5 
246.4 
250.0 
249.4 
255.8 
255.1 
245.7 
247.1 
252.9 
116 
N, Raman and S. N. H. Azmi: Method for dclcrminalion of nifedipine in pure form and in pharmaceutical preparations, Ada Pharm. 
49 (1999)llJ-118. 
Tab\e 11. Determination of nifedipine 
Preparation' 
Nicardia Retard-10 
Adalat Retard-10 
Calciguard-10 
Amourit taken 
(Mg mL-') 
10.0 
10.0 
20,0 
10.0 
10.0 
20,0 
10.0 
10.0 
20.0 
in pharmaceu itical 
Amount added 
(Mg mL-' 
15.0 
20.0 
20.0 
IS.O 
20.0 
20.0 
15.0 
20.0 
20.0 
') 
preparations by standard addition 
Total amount found 
(Mg mL-')" 
24.92 
30.01 
40.14 
25.05 
30.01 
39.98 
25.32 
29.84 
40.10 
Recovery 
(%) 
99.7 
100.0 
100.4 
100.2 
100.0 
100.0 
101.3 
99.5 
100.3 
method 
RSD 
(%)" 
0.3 
0.6 
0.3 
0.6 
0.6 
0,6 
1.1 
0,5 
1,2 
' Drug samples arc in tablet form, 
'' Three independent analyses. 
Table III. Determination of nifedipine in dosage forms by the prosposed kinetic method and 
reference method 
Preparation 
Nicardia Retard-10 
Adalat Retard-10 
Calciguard-lO 
Nominal 
composition 
(mg) 
10 
10 
10 
Kinetic method 
Recovery 
(%) 
99,9 
100,3 
100.6 
RSD 
0,6 
0.9 
1,1 
fb 
0,536 
0,604 
1.166 
Reference method 
Recovery 
(%) 
100,0 
100.0 
100.1 
RSD , 
0,1 0,485 
0,1 0,485 
0.1 1.579 
" Five independent analyses, 
'' I' value at 95% confidence level is 2,776, 
The calculated f-test values which did not exceed the theoretical value have indi-
cated the absence of any significant difference in terms of accuracy. 
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SAtETAK 
Metoda odredivanja nifedipina u fistoj tvari i u farmaceutskim pripravcima 
NAFISUR RAHMAN I SYED NAJMUL HEJAZ AZMI 
Opisana je nova metoda za odredivanje nifedipina. Metoda se temelji na oksidaciji 
nifedipina pomodu kalijevog permanganata u neutralnoj sredini i spektrometrijskom 
pradenju promjene absorbancije na 530 nm. Kalibracijski graf je linearan u koncentra-
cijskom podru^u od 18-44 ng naL"^ Metoda je primjenjena za odredivanje nifedipina u 
farmaceutskim pripravcima. 
KljuCne rijeHi: nifedipin, odredivanje, tableta 
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Abstract 
Three simple and sensitive extractive spectrophotometric methotJs have been'dMcri^gd/or the assay of diltiazem 
hydrochloride either in pure form or in pharmaceutical formulations. The d«felQpe'4^methods involve formation of 
coloured chloroform extractable ion-pair complexes of the drug with brpm.plfiymol olue (BTB), bromophenol blue 
(BPB) and bromocresol green (BCG) in acidic medium. The extracted complexes showed absorbance maxima at 415 
am for all three methods. Beer's law is obeyed in the concentration ranges 2.5-20.0, 2.5- 10.0 and 2.5-12.5 ng ml ^ ' 
with BTB. BPB and BCG, respectively. The methods have been applied to the determination of drug in commercial 
tablets and capsules. Results of analysis were validated statistically and through recovery studies. C 2000 Elsevier 
Science B.V. All rights reserved. 
Keywords: Diltiazem hydrochloride; Bromothymol blue; Bromo'plwnol Mpe; Bromocresol green; Spectrophotometry 
1. Introduction 
Diltiazem, (-|- )-5-[2-(diiTiethylamino)ethyl]-c!i, 
2,3-dihydio-3-hydiuxy-2-0)-methoxyphenyl)-1,5-
bcnzothiazepin-4(5//)-one aceUte-raoiiohydrochl-
oride, is a calciun:\ chaniit^el*1ant^g,Qnist and widely 
used in the treatment <i{it\yi\mi^'pzi of cardiova-
scular disease. The drug and its formulations are 
•Corresponding author. Tel.: + 91 •57I-400-5I 5. 
E-mail n(/(/rcv.(.'chl I 7nr@aniii.up.nic.in (N. Rahman). 
listed in USP [1] and assayed by HPLC method. 
The drug has been determined by a variety of 
analytical techniques such as HPLC [2-7], gas 
chromatography [8,9], capillary electrophoresis 
[10], HPTLC [11], polarimetry [12] and titrimetry 
[13]. Spectrophotometric methods provide practi-
cal and significant economic advantages over 
other methods. The drug content in pharmaceuti-
cal preparations has been determined by two spec-
trophotometric methods [14] which are based on 
the formation of coloured complex of the drug 
with cobalt thiocyanate and methyl orange. The 
0731-7085/00/5 • see fiunl matter © 2000 Elsevier Science B.V. All rights reserved. 
Pll: S073I -7085(00)00409-X 
2 N. Rahman el al. /J. Pharm. Biomed. Anal. 000 (2000) 000-000 
Table 1 
Optical and regression characteristics, precision and accuracy of the proposed methcxls 
Parameters 
'^ ™. (nm) 
Beer's law limit (ng ml~') 
Molar absorptivity 0 mol"' cm"') 
Linear regression equation* 
Correlation coefficient 
Relative standard deviation (%)" 
Recovery (%) 
Extraction methods with 
BTB 
415 
2.5-20,0 
2.25 xlO" 
/ I - 0 . 0 0 + 0.050 C 
0.9996 
1.00 
100.16 
BPB 
415 
2.5-10.0 
2.71x10^ 
^ - 0 . 0 0 + 0.060 C 
0.9996 
1.13 
99.96 
BCG 
415 
2.5-12.5 
2.53x10* 
X-0.00+0.056 C 
0.9988 
1.03 
100.28 
' With respeci lo A -a + hC, where C is the concentration (jig ml~') and A is absorbance. 
^Ten replicate samples. 
coloured species are extracted into organic sol-
vents and measured at 630 and 420 nm with 
cobalt thiocyanate and methyl orange, respec-
tively. Sastry and coworkers [15] have described 
two spectrophotometric methods for its determi-
nation based on the oxidation of diltiazem hydro-
chloride by Fe(lII) or A^-bromosuccinihiide and 
estimating the reduced Fe(II) with 1,10-phenan-
ihrolinc or tinreacted iV-bromosuccinimide with 
metol-sulphanilamide, respectively. The acetate 
moiety in the drug is converted into ferric hydrox-
amate and hence estimated spectrophotometri-
cally [16]. It was also determined in 
pharmaceutical preparations on the basis of reac-
tion of hydrolyzed diltiazem hydrochloride with 
P'olin-Ciocalteau reagent [17]. Other extractive 
spectrophotometric methods [18,19] are also uti-
lized for its assay in dosage forms. However, 
many of these assay methods are limited in their 
applications or are rather tedious and time con-
suming. There is, therefore, a need for a simple 
spectrophotometric method for the iassay of dilti-
azem hydrochloride in pharmaceutical 
preparations. 
In this paper we propose, three :simple and 
sensitive extractive spectrophotometric methods 
for the assay of diltiazem hydrochloride. The 
methods arc based on ion-pair complexes of drug 
with dyestuffs such as brbmbthymol blue (BTB), 
bromophenol blue (BPB) and bromocresol green 
(BCG) and subsequent extraction into chloroform 
under reaction conditions used. 
2. ExperimeDtal 
2. J. Apparatus 
Spectronic 200"^ spectrophotometer (Milton 
Roy, USA) and an EUco model Li-10 pH meter 
' < > I I I I I I I I 11 I I I I I I I I < I < > • I > M I I 1 I 
XfOM wtaa 430100 900.40 
WATeleoictb. -am 
Fig. 1. Absorption spectra of diltiazem hydrochloride-dye 
complex extracted into 10 ml chloroform: (a) drug— 12 jig 
m l - ' + 5 ml of 0.025% BTB+ 5 ml of pH 2.8 buffer; (b) 
drug - 9 n g r a l - ' + 5 m l o f 0.025% BPB + 5 ml of pH 2.5 
buffer; (c) drug - 9.6 ng ml"' + 5 ml of 0.025% BCG + 5 ml 
of pH 3.5 buffer. 
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were used for absorptiometric determination and 
pH measurement, resj)ectively. 
2.2. Reagents and buffer solutions 
The dyestufTs were used as 0.025% solutions of 
bromothymol blue (BTB), brompphenol blue 
(BPB) and bromocresol green (BCG), all in dou-
bly distilled water. 
Sodium acetate-hydrochloric acid buffers [20] 
of pH 2.5, 2.8 and 3.5 were prepared by mixing 50 
ml of 1.0 M sodium acetate solution with 50.50, 
49.50 or 46.25 ml, :Tespaitiyely, of 1.0 M HCl 
solution and diluted to 250 ml with doubly dis-
tilled water. ThepH of each solution was adjusted 
to an appropriate value with the aid of a pH 
meter. 
2.3. Test solution 
As a test solution, 0.1 mg ml ~' diltiazem hy-
drochloride (Sigma, USA) was prepared freshly in 
doubly distilled water. 
Analytical grade chloroform was used for 
extraction. 
2.4. Procedure for calibration curve 
Into a series of 50-ml separating funnels, 5 ml 
of buffer solutions of pH 2.8 (pH 2.5 or pH 3.5) 
and 5 ml of BTB (BPB or BCG) were placed. An 
appropriate volume of 0.01% drug solution (0.25-
2.00 ml for BTB; 0.25-1.00 ml for BPB; 0.25-
1.25 ml for BCG) was added to each funnel and 
mixed well. The funnels were shaken vigorously 
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with 10 ml chloroform for 2 min, then allowed to 
stand for clear separation of the two phases. The 
absorbance of the organic phase at 415 nm was 
measured in each case against a reagent blank 
similarly prepared. The calibration graphs are lin-
ear over the concentration ranges and are given in 
Table 1. The colour is stable for at least 3 h. 
2.5. Procedure for the a.i.<iay of dosage form.<! 
An amount of the tablet or capsule powder 
equivalent to 25 mg diltiazem hydrochloride was 
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Fig. 3. Effect of pH: (a) 12 >ig ml"' drug+ 5 ml of 0. 025% 
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pH values; (c) 6 jjg ml - ' drug + 5 ml of 0.025% BCO + 5 ml 
buffer of different pH values. Each set is extracted into 10 ml 
chlorofonn. 
weighed accurately, and extracted into 50 ml chlo-
roform with shaking. Filtration through a What-
man No. 42 filter paper was performed. The 
filtrate was evaporated to dryness under vacuum 
and the residue was taken up with doubly distilled 
water and transferred to a 250-ml standard volu-
metric flask, diluting to volume. The assay was 
completed using the procedure described in Sec-
tion 2.4. 
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Fig. 4. Influence of the volume of 0.025% dye: (a) BTB, (b) 
BPB, (c) BCG. 
3. Results and discosston 
Diltiazem hydrochloride forms ion-pair com-
plexes in acidic buffer with dyestuffs such as 
bromothymol blue (BTB), bromophenol blue 
(BPB) and brpmocr^sol green (BCG) and these 
complexes are qiiahtitatively extracted into chlo-
roform. The absorption spectra of the ion-pair 
complexes extracted into chloroform are shown in 
Fig. 1. The ion-pair complexes with BTB, BPB 
and BCG absorbed maximally at 415 nm. The 
reagent blank under similar conditions showed no 
absorption. 
In order to establish molar ratio between dilti-
azem hydrochloride and dyestuffs used, the 
Table 2 
Comparison of molar absorptivities and Beer's law limits of the proposed methods with those from other spectrophotomelric 
methods for the determination of diltiazem hydrodiloride 
Reagent •^ m.^  (n™) Beer's law limit (jig ml~') Molar absorptivity (1 mol~' cm"') Reference 
Ferric hydroxamate 500 50-800 
Cobalt (hiocyanate 630 60-600 
Methyl orange 420 5-60 
Feai>-l,IO.pbenanthro!ine 495 1-10 
Metol-sulphanilamide 520 2-24 
Bromothymol blue 415 2.5-20 
Bromophenol blue 415 2.5-10 
Bromocresol green 415 2.5-12.5 
4.85x10^ 
7.30 X \Cf 
7.96 X 10' 
2.93 X Iff" 
1.35x10* 
2.5 X 10* 
2.71x10* 
2.53x10* 
1161 
[14] 
[14] 
[15] 
(15) 
This work 
This work 
This work 
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method of continuous variations p i l has been 
applied. In tbis method, solutions of drug and 
dyestuff with identical molar concentrations were 
mixed in varying volume ratios in such a way that 
the total volume of each mixture was the same. 
The absorbance of each solution was measured 
and plotted against the mole fraction of the drug, 
[drug]/[drug] + [dyestuff]; (Fig. 2). This measure-
ment showed that 1:1 complex was formed with 
each dyestuff. The formation constants [22,23] 
were also estimated and found to be 1.98 x 10*, 
1.46 X 10* and 1.56 x 10* for complexes with BTB, 
BPB and BCG, respectively. 
Diltiazcm hydrochloride contains tertiary amino 
group which is protonated in acid medium, while 
sulphonic acid group is present in BTB: that is the 
only group undergoing dissociation in the pH 
range 1-5. BPB and BCG are examples of sul-
phonephtbalein type of dye. The colour of such 
dyes is due to the opening of lactoid ring and 
subsequent formation of quinoid group. It is sup-
posed that the two tautomers are present in equi-
libriiun but due to strong acidic nature of the 
sulphonic acid group, the quinoid body must 
predominate. Finally the protonated diltiazcm hy-
drochloride forms ion-pairs with the dyestuffs 
which are quantitatively extracted into chloro-
form. The possible reaction mechanisms are pro-
posed and given in Scheme 1. 
The influence of pH on the ion-pair formation 
of diltiazcm hydrochloride with various dyestufTs 
has been studied using sodium acetate-hydrochlo-
ric acid buffer. The results are shown in Fig. 3. It 
is evident that absorbance of complexes with BTB, 
BPB and BCG was found to be constant within thes 
pH ranges 2.2-3.3, 2.0-3.0 and 2.8-3.8, respec-
tively. Thus, al! the absorbance measurements 
were made at pH 2.8, 2.5 and 3.5 with BTB, BPB 
and BCG, respectively. 
The effect of dyestufT concentrations was also 
studied by adding different volumes of dyestuff to 
a constant amount of diltiiazem hydrochloride (60 
Mg). It is apparent from Fig. 4 that the maximum 
absorbance, in each case, was found with 2.0 ml of 
dyestuff, beyond which absorbance was constant. 
Thus, 5 ml of each dyestuff was used for ion-pair 
formation throughout the experiment. 
In the conditions mentioned above, the main 
merits of the procedures proposed for determina-
tion of diltiazcm hydrochloride have been estab-
lishecl. Table 1 summarizes tbe values for Beer's 
law limits, molar absorptivity, regression equation, 
corVelation coefficients, relative standard deviation 
and recoveries. To test the reproducibility of the 
proposed niethods, ten replicate determinations of 
60 Jig of diltiazem hydrochloride were made. The 
coefficient of variation was found to be less than 
1.2% for all the procedures. 
The comparison of molar absorptivities and 
Beer's law limits of the proposed methods with 
those from other spectrophotometric methods is 
presented in Table 2. It can be seen from the table 
that those methods having broad dynamic linear 
range offered lower sensitivities, expressed as mo-
lar absorptivities. However, the methods proposed 
in this paper present higher sensitivities with nar-
row analytical range but are comparable to other 
spectrophotometric methods [15]. The validity of 
the proposed methods has bec^ tested by sundard 
addition method. The restilts are suinmarized in 
Table 3. 
A systematic study of ithe effect of foreign 
species present alongwith <filtiazcm hydrochloride 
on the detenniiiiticinof diltiazem hydrochloride at 
9.0 ng ml"! leveliWas iindcrtakcn. This study was 
carried out by following the proposed procedures 
for a lO i^bl sample system, by adding a known 
amount of foreign species to a diltiazem hydro-
chlorid^Lsolution of 9.0 fig ml "'. Table 4 summa-
rizes the results obtained. However, the drug 
content from the powdered tablets or capsules was 
extracted into chloroform, which completely re-
rhoves any interference by the common excipients 
found in formulations. 
Table 4 
EfTea of foreign species on the detennioatioa of 9.0 tig ml"' 
diltiazem hydrochloride 
Foreign species Maximum tolerance limit (mg)* 
Glucose 
Sucrose 
Fructose 
Lactose 
Starch 
27.0 
51.3 
27.0 
54.1 
16.2 
* The same level was found for all the proposed procedures. 
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The proposed methods have been successfully 
applied to the determination of diltiazem hydro-
chloride in pharmaceutical preparations. The per-
formance order of the proposed methods is 
BPB > BCG > BTB. The results obtained and 
sViown in Table 5 were compared to those ob-
tained by a reference method [16] by means of 
/-test at 95% confidence level. In all cases, the 
average results obtained by proposed methods 
and reference method were statistically identical, 
as the difference between the average values had 
no significance ,at 95% confidence level. 
The proposed methods are simple, sensitive and 
reprc^ucible and can be used for routine analysis 
of dmazem hydrochloride in pure form and in 
formulations. 
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Abstract 
A spectrophotometric method for the determination of diltiazem hydrochloride has been developed. The drug is 
boiled with sodium metavanadate in sulfuric acid medium (11.0 M) for 20 min and the absorbance is measured at 750 
nm. Beer's law is obeyed up to 50 ^.g ml" ' with R.S.D. of 1.07% and molar absorptivity, 6.18 X IQ-* 1 mol ' cm '. 
The method was applied to the determination of the drug in commercial tablets and capsules. © 2000 Elsevier 
Science B.V. All rights reserved. 
Keywords: Diltiazem hydrochloride; Spectrophotometry; Sodium metavanadate; Pharmaceutical preparations 
1. Introduction 
Diltiazem, (+ )-5-[2-(dimethylamino)ethyl]-c«, 
2,3-dihydro-3-hydroxy-2-(;7-methc0yphenyl)-l,5-
benzothiazepin-4(5H)-one acetate monohydro-
chloride, is an important coronary vasodilator 
drug of the calcium channei-blocker, used in the 
therapy of heart disease and hypertension [1], 
The compound also exhibits weak negative in-
otropic and chronotropic actions as well as a 
* Corresponding author. Tel. +354-571-400515. 
E-mail address: chtl7nr@amu.up.nic.in (N. Rahman) 
weak hypotensive activity [2-4]. Therefore, its 
analysis in drug formulations is very important. 
The drug and its tablet formulations are official 
in the United States Pharmacopeia XXIII [5]. 
The other methods for its estimation include gas 
chromatography [6,7], high performance liquid 
chromatography [8-12], high performance thin 
layer chromatography [13], titrimetry [14] and 
polarimetry [15]. 
The estimation of diltiazem hydrochloride in 
pharmaceutical preparations was also made by 
less expensive techniques such as spectropho-
tometry. The drug contains the acetate moiety 
and is determined spectrophotomctrically by the 
0026-265X/00/S - sec front matter © 2000 Elsevier Science B.V. All rights reserved. 
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ferric hydroxamate method [16]. Sastry et al. [17] 
have described two spectrophotometric methods 
for the determination of diltiazem hydrochloride 
based on its oxidation with a known excess of 
Fe(III) or A^-bromosuccinimide and estimating the 
reduced, Fe(II) or unreacted A^-bromosuccini-
mide with 1,10-phenanthroline or metoi-sul-
fanilamide, respectively. It is also determined [18] 
by treatment with cobalt thiocyanate at pH 3 
followed by extraction with toluene. The blue 
colored chromogen absorbs maximally at 627 nm 
and Beer's law holds in the range 100-600 |jLg 
ml"'. The other extractive spectrophotometric 
methods [19,20] are also utilized for its determi-
nskVion m phaimacc\ilka\ prepaiaUons. 
The present paper describes the spectrophoto-
metric determination of diltiazem hydrochloride 
with sodium metavanadate in sulfuric acid 
medium. The method is also applied to determi-
nation in pharmaceutical preparations. 
2. Experimental 
2.1. Apparatus 
All spectral and absorbance measurements 
were made on spectronic 20 D * spectrophotome-
ter (Milton Roy, USA) with 1 cm matched quartz 
cells. 
2.2. Reagents 
Sodium metavanadate, 1.0 M, was prepared by 
dissolving 13.995 g of sodium metavanadate in 
boiling sulfuric acid and diluting to 100 ml with 
II.OMH2SO4. 
2.3. Test solution 
solution were pipetted. To each test tube 2.6 ml 
of sodium metavanadate solution and 4 ml of 13 
M H2SO4 were added, mixed well and boiled 
gently for 20 min on a water bath. After heating 
for 20 min, the solutions were cooled at room 
temperature and transferred to a 10-ml volumet-
ric flask and diluted to volume with doubly dis-
tilled water and the absorbance was measured at 
750 nm against a reagent blank treated similarly. 
2.4.1. Procedure for the assay of capsules and tablets 
An accurately weighed quantity of the mixed 
contents of five capsules or five powdered tablets, 
equivalent to 60 mg of the drug, was extracted 
into 50 ml cWoToform with shaking and ths 
residue filtered using Whatman No. 42 filter pa-
per. The filtrate was evaporated to dryness and 
the residue was taken up with doubly distilled 
water and transferred to a 50-ml volumetric flask, 
diluting to volume. The assay was completed fol-
lowing the recommended procedure. 
2.4.2. Procedure for reference method 117} 
Aliquots of 0.1-1.0 ml of 0.1% diltiazem hydro-
chloride were pipetted into a series of 10-ml 
boiling test tubes. Into each test tube 1.5 ml of 
0.003 M ferric chloride and 2.5 ml of 0.01 M 
1,10-phenanthroline were added successively. The 
contents of each test tube were mixed well and 
heated on a boiling water bath for 30 min. After 
cooling the test tubes at room temperature, the 
solutions were transferred to 10-ml volumetric 
flasks. Then, 2 ml of 0.02 M orthophosphoric acid 
was added to each flask and diluted to the mark 
with doubly distilled water. The absorbance was 
measured against a reagent blank at 495 nm. The 
amount of the drug in a given sample was com-
puted from its calibration curve. 
Diltiazem hydrochloride (1.2 mg ml"') (Sigma 
Chemical Co., USA) was prepared freshly in 
doubly distilled water. 
2.4. Procedure 
Into a series of boiling test tubes different 
volumes, corresponding up to 50 |jLg ml"', of drug 
3. Results and discussion 
The proposed method has been used for the 
determination of diltiazem hydrochloride by oxi-
dation with sodium metavanadate in sulfuric acid 
medium. The blue color formed is due to the 
reduction of vanadium(V) to vanadium(IV) by 
diltiazem hydrochloride in sulfuric acid medium. 
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The optimum conditions for the formation of 
blue color were studied and maintained through-
out the studies. An investigation of the effect of 
reaction time showed that maximum color was 
obtained when the reaction mbcture is boiled gen-
tly for 20-25 min on a water bath. The color 
developed is measured at room temperature after 
dilution and mixing. The color is stable for 5 h. 
The effect of reagent concentration was studied 
by adding different volumes of sodium metavana-
date solution to a constant amount of 500 |xg per 
10 ml of diltiazem hydrochloride. It was found 
that a maximum absorbance of the blue color was 
with 2.5 ml of reagent, beyond which absorbance 
was constant. Therefore, 2.6 ml of sodium meta-
vanadate was used throughout the experimental 
observation. 
The second variable in color development was 
the concentration of sulfuric acid. An investiga-
tion of the acidity showed that 7.9-8.5 M HjSO^ 
was sufficient to develop the color. 
The absorption spectrum under the optimized 
condition showed a maximum at 750 nm with a 
molar absorptivity, 6.18x 10^ 1 mol"' cm"'. The 
absorbance measurements of the standard drug 
solution were made at 750 nm and a calibration 
curve was constructed by plotting absorbance vs. 
concentration of the drug in micrograms per 
milliliter. Beer's law is obeyed up to 50 .^g ml"'. 
The linear regression equation obtained was A = 
0.00 -f- 0.0137C (where C = concentration of dilti-
azem hydrochloride in micrograms per milliliter), 
the correlation coefficient being r = 0.999, indi-
cating an excellent linearity. 
The detection limit for the proposed method 
was found to be 0.02 \i.g ml"', which was calcu-
lated by using the following relationship [21]: 
Detection limit 
' " « - ! b 
where n = number of samples; b = slope of line 
of regression; t = student's /-value at 95% confi-
dence level; Sl = wanance = T.(A-A^^^^y/n-2 
[22]; {A = experimental value of absorbance; 
/4 (.gig = absorbance value calculated from the re-
gression equation). 
The small value of variance, 3.84 X 10"*, con-
firmed the small degree of scatter of experimental 
data points around the line of regression. Both 
the detection limit and the slope of the calibra-
tion graph indicate the good sensitivity. 
The reproducibility of the method was calcu-
lated in terms of percent relative standard devia-
tion (%R.S.D.) from the absorbance level of 10 
different solutions at concentration level of 30.0 
Table 1 
Determination of diltiazem hydrochloride in pharmaceutical preparations by standard addition method 
Preparation' 
Dilcardia-30 
Angizem-30 
Diltime-30 
Dilzem-30 
Dilcontin-60 
Kaizem CD 90 
Dilter CD 90 
Amoimt taken 
((J-g 
12 
12 
12 
12 
12 
12 
12 
12 
12 
12 
12 
12 
12 
12 
ml"') 
Amount added 
( ( i g m l " ' ) 
18 
30 
18 
30 
18 
30 
18 
30 
18 
30 
18 
30 
18 
30 
Total amount found 
( jxgml" ' ) 
29.75 
41.77 
29.72 
41.74 
30.09 
42.06 
29.56 
41.74 
30.09 
41.92 
29.92 
41.87 
29.92 
41.89 
Recovery 
(%) 
99.16 
99.46 
99.08 
99.39 
100.31 
100.15 
98.53 
99.39 
100.31 
99.80 
99.74 
99.69 
99.74 
99.74 
R.S.D. 
(%)" 
0.610 
0.445 
0.610 
0.347 
0.618 
0.252 
0.744 
0.347 
0.618 
0.360 
0.484 
0.265 
0.484 
0.346 
Drug samples are in tablet and capsule form. 
''Three independent analyses. 
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Table 2 
Determination of diltiazem hydrochloride in dosage forms by the proposed method and reference method 
diM^ 
Preparation Nominal 
compositiQii^ 
Proposed m e t h o d y ^ ^ -
Recovery ( % ^ R!S.D.(%) /" 
Reference method [17] 
Recovery (%) RS.D. (%)" (" 
Dilcardia-30 
Angi2em-30 
Diltime-30 
Dilzem-30 
Dilcontin-60 
Kaizem CD-90 
Dilter CD-90 
30 
30 
30 
30 
60 
90 
90 
99.76 
99.45 
100.16 
99.74 
99.98 
99.55 
99.88 
0.756 
0.630 
0.582 
0.385 
0.383 
0.677 
0.384 
0.692 
2.023 
0.638 
1.555 
0.194 
1.549 
0.194 
99.68 
99.58 
100.16 
100.06 
100.06 
99.88 
100.08 
0.980 
0.809 
0.974 
0.805 
0.805 
1.050 
0.805 
0,763 
1.200 
0.382 
0.185 
0.185 
0.283 
0,185 
"Five independent analyses. 
"( value at 95% confidence level is 2.776. 
(ig m r ' and the value was found to be 1.07%. 
The drug content from the powdered tablets or 
capsules was extracted with chloroform, which 
completely eliminates any interference by the 
common excipients found in formulations. 
The validity of the proposed method was per-
formed by using the standard addition technique. 
The results are summarized in Table 1. 
The applicability of the proposed method was 
assayed by analyzing commercial tablets and cap-
sules. The assays were carried out as described 
under the experimental procedure for dosage 
forms. In all the preparations, the amount of 
diltiazem hydrochloride was obtained by direct 
measurement using the standard calibration curve. 
For the sake of comparison, the diltiazem hydro-
chloride content of the pharmaceutical prepara-
tions was also determined by a reference method 
[17]. In all of the pharmaceutical preparations, 
the results were found to be very good (Table 2),' 
thus confirming the validity of the proposed 
method. 
A statistical comparison between results ob-
tained from both the proposed and reference 
methods was carried out. The calculated /-values 
did not exceed the theoretical values at the 95% 
confidence level, indicating the absence of any 
difference between the two methods. 
The procedure described here provides a rapid 
method for determination of diltiazem hydrochlo-
ride in bulk and dosage forms because of its 
simplicity, accuracy and reproducibility. The pro-
posed method is comparable to other spectropho-
tometric methods [16,17] with respect to analysis 
time and does not require the prior extraction 
needed in some other methods [18-20]. It also 
provides practical and significant economic ad-
vantages over other instrumental methods. The 
method is, thus, suitable for routine analysis of 
diltiazem hydrochloride tablets and capsules. 
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